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1. INTRODUCTION 
 
Siddha system of medicine is a most primitive, ancient system of medicine. which 
deals with the diseases of humanbeings efficiently with the knowledge of both subtle 
and also the gross material body
[1]
 
   
Siddha means achievement or perfection.siddha system is largely therapeutic in 
nature and its origin can be traced back to birth of human race on the planet
 [1].
. 
                
The origin of the Siddha system dates back BC 10,000- BC 4000, according to 
Thiru T.v. sambasivam pillai Siddha medical dictionary. The word Siddha comes 
from the word siddham
 [1].
. 
The system is believed to be developed by 18 siddhars.One who had attained 
perfection in life is called siddhar. Siddhars are indeed true scientists who discovered 
and displayed god to the common people through their divine wisdom, medicines and 
elixirs with which they treated the incurable diseases of mankind
 [1].
. 
Siddhars had eight supernatural powers, such as Anima, Magima, Lagima, 
etc., essential for their goal, as mentioned in Silappathigaram.  They are the greatest 
men holding tremendous powers in themselves by way of yoga practice and 
rejuvenation
 [1].
.  
According to Siddha science, the human body is composed of five primordial 
elements viz.,  
Earth, Water, Fire, Air and Ether. 
The following instances will show the transformed conditions of the five elements in 
the human body
 [1].
: 
1. Earth - Bones, flesh, nerves, Skin and Hair. 
2. Water - Bile, Blood, Semen, Secretion and Sweat 
3. Fire - Hunger, Thirst, Sleep, Beauty and Indolence. 
4. Air - Contraction, Expansion and Motion. 
5. Ether - Interspaces of the stomach, Heart and the Head. 
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They are the fundamental principles of creation, preservation and destruction in the 
universe.  
 
Á¢¸¢Ûõ Ì¨ÈÂ¢Ûõ §¿¡ö¦ºöÔõ á§Ä¡÷ 
ÅÇ¢ Ó¾Ä¡ ±ñ½¢Â ãýÚ. 
                            - ¾¢ÕìÌÈû.[23] 
 
According to this system of medicine, the human body is made up on three 
humours- Vaatham, Pitham, and Kabam. 
1. The humour responsible for creative activity in the physical body is known as 
Vaatham. 
2. The humour responsible for protective activityis known as Pitham. 
3. The humour responsible for destruction activity against pathogens is called 
Kabam. (Phelgm) 
In normal healthy condition ratio between them being 1:1/2:1/4.  
"ÅÆí¸¢Â Å¡¾õ Á¡ò¾¢¨Ã ¦Â¡ýÈ¡¸¢ø 
¾Æí¸¢Â À¢ò¾ó ¾ýÉ¢Ä¨Ã Å¡º¢ 
«ÆíÌí ¸Àó ¾¡É¼í¸¢§Â ¸¡§Ä¡Êø 
À¢Èí¸¢§Â º£Å÷ìÌõ À¢º ¦¸¡ýÚÁ¢ø¨Ä§Â" 
       -Ì½Å¡¸¼õ[3].  
The equilibrium of humours is considered as healthy and conditions their 
disturbance or imbalance leads to disease condition. 
In siddha system of medicine the importance of dietary habits are also well 
emphasiszed for the disease management and prevention.                                        
                           “¯½§Å ÁÕóÐ ÁÕó§¾ ¯½×”. 
Siddhars classified the diseases into 4448 and established a separate 
chapter.As per Sababathy kaiyedu,One  such  clinical entity is keel vayu
[4]
.According 
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to Siddha Maruthuvam(Pothu)
 
the signs and symptoms of KEEL VAYU  is,  
pain&sweliing in knee joints, morning stiffness,  restricted movement, difficulty to 
walk, can be correlated with OSTEO ARTHRITIS(KNEE) in Modern Science
[4]
.  
OSTEO ARTHRITIS is the most common form of arthritis.  Approximately 
80-90% of individuals older than 65 years have evidence of primary OA. In India 
knee osteoarthritis is more common in females than males and it the most frequent 
joint disease with prevalence of   22-39%
 [5]
. 
Since large number of patients with OA (100 Patients/day) are reporting the 
OPD of Ayothidoss Pandithar Hospital, which made me to select this disease for my 
dissertation work. So I have chosen the drug poora parpam for my clinical trial in 
keelvayu.  In the text veeramamunivar vagada thiratu “POORA PARPAM “a siddha 
formulation has been specifically indicated for KEELVAYU. The mode of 
preparation  seems to be simple  and cost effective. The main Ingredients of the above 
said formulation are Pooram (calomel), latex of Calotropis gigantean have anti vadha 
properties as per siddha literature. 
The safety Studies of  POORA PARPAM   been completed as a Dissertation  
work at NIS(Referrence:Dissertation -187(D), DR.MGR MEDICAL UNIVERSITY 
reg no:32093606,April-2012 , Department of nanju noolum maruthuva neethu 
noolum,National Institute of Siddha, chennai-47.and the trial drug has not yet 
undergone for  any clinical trial in osteo arthritis
[10]
. 
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2.OBJECTIVE 
 
a. PRIMARY OBJECTIVE: 
 To study the siddha formulations ―POORA PARPAM” (Internal Medicine) 
& NATHAICHOORI ENNAI (External Medicine) in the treatment of 
―KEEL VAYU‖(osteo arthritis) for the reduction of pain,swelling and to 
improve the range of movements. 
b. SECONDARY OBJECTIVE: 
 To study Keelvayu, on the basis of Envagai thervu, mukkutram, kalam, naadi, 
Neerkuri, Neikuri etc,, in order to evaluate the pathology. 
 To assess the predominance of the disease related to age, sex, socio-economic 
status, occupation and family history etc,. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Review of Literature 
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3.REVIEW OF LITERATURE 
SIDDHA ASPECTS  
The concepts of siddha system are based on fundamental principles of 96 
thathuvams. According to this thathuvams Universe originally consisted of atoms 
which contributed to the five basic elements named as pancha boothas individually 
have the name of Earth, water, fire, air, and ether which corresponds to the five sense 
of the human. 
Pancha poothas are the foundations for three humours (vaatham, piththam, kabam) 
which are the basic elements that support our body structure. 
 Vaayu & Aagayam both constitute vaatham 
 Theyu alone constitutes piththam  
 Appu & Mann both constitute kabam. 
The normal ratio of Vaatham, Pitham and Kabam is 1: 1/2:1/4 respectively 
[3]
. 
 When the hormony of the above said humours gets deranged owing to a 
relative increase or decrease of one or more of the principal humours, disease is 
caused.  
The signs and symptoms are produced according to the particular deranged 
humours. 
 KEEL VAAYU
 [4]
 
In Siddha literature keel vaayu has been described under Vaatha diseases.  
Keel vaayu is the general term that includes all kinds of joint disorders. 
Description of the nomenclature 
Keel                =   Joint 
Vaayu            =   Vatham 
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 The joint is initially affected by the vitiated Vaatham. Pitham and Kabam 
accompany later. It is a disease which is common in Pitha kaalam (middle 1/3 of the 
lifespan- 33 to 66 years). 
TYPES OF KEEL VAAYU 
There are ten types of keelvayu which are mentioned in the textbook 
“SIDDHA MARUTHUVAM”. 
The 10 types are mentioned as below 
1. Vali keel vaayu 
2. Azhal keel vaayu 
3. Iyya keel vaayu 
4. Vali Azhal keel vaayu 
5. Vali Iyya keel vaayu 
6. Azhal Vali keel vaayu 
7. Azhal Iyya keel vaayu 
8. Iyya Vali keel vaayu 
9. Iyya Azhal keel vaayu 
10. Mukkutra keel vaayu 
AETIOLOGY: 
1. Environmental factors [21]: 
"Å¡¾ Å÷ò¾É ¸¡Ä§Á§¾¡ ¦ÅýÉ¢ø 
     ÁÕ×¸¢ýÈ ¬É¢ ¸ü¸¼ Á¡¾õ 
¬¾¨Éô Àº¢§Â¡Î ¸¡÷ò¾¢¨¸ ¾ýÉ¢ø 
     ¬¼Õ§Á ÁüÈ Á¡¾í¸û ¾ýÉ¢ø 
§À¡¸§Å ºÁ¢ì¸¢ýÈ ¸¡Ä Á¡Ìõ" 
- ä¸¢¨Åò¾¢Â º¢ó¾¡Á½¢ 
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In this siddha literature YOOGIMUNI said that the Vaatha diseases are 
precipitated in the months from Aani to Karthigai (June to December), hence the 
seasonal factors are involved and facilitate the Vaatha diseases. 
"ÀÐÁò¨¾ô âì¸ ¨ÅìÌõ À¡ÛÁ¢¸ì ¸¡Ôõ 
ÓÐ§ÅÉ¢ü Ä¢üÒÅ¢¿£÷ ÓüÚõ - ¸Ð¦ÁÉ 
ÅüÚõ ¸ÀÁ¢Ìõ Å¡ÔÁ¢Ìõ Å¡úÁ¡ó¾Ãíì 
ÌüÈ ¿Ä¢ì §¸¾¢¦¾ý §È¡Ð" 
         -º¢ò¾ ÁÕòÐÅ¡í¸ ÍÕì¸õ[18] 
In muthuvenil kalam due to the increased solar radiation leads to increased  
evaporation of water content from the body . In turn increases the kabam and vatham 
thathus from their normal level resulting in the production of vaatha diseases. 
 
DIET
[16]
. 
Vatha disease is caused due to the following reasons:  
¦¾¡Æ¢ø ¦ÀÚ ¨¸ôÒ¸¡÷ò¾ø  ÐÅ÷ò¾ø Å¢Íí¸¢Ûí§º¡Úõ 
      À¨ÆÂ¾¡õ ÅÃÌ Áü¨Èô ¨Àó¾¢¨É ÂÕó¾¢É¡Öõ 
±Æ¢ø ¦ÀÈô À¸ÖÈí¸¢ þÃÅ¢É¢ÖÈí¸¡¾ ¾¡Öõ 
      Á¨Æ¿¢¸¡ ÌÆÄ¢É¡§Ä Å¡¾í§¸¡ À¢ìÌí ¸¡§½ 
        - ÀÃÃ¡º§º¸Ãõ 
• Excessive intake of tubers  
• Excessive intake of chill foods  like  curd. 
• Wandering in chill air in evening time 
• Getting drenched in rain 
• Living in hilly region 
• Excessive sexual  desire with  ladies  
• Heredity 
•  
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ÅÇ¢¾Õ ¸¡ö¸¢ÆíÌ Å¨ÃÅ¢Ä¡ ¾Â¢Äø §¸¡¨Æ 
ÒÇ¢¾Â¢÷ §À¡ýÁ¢ÌìÌ Ó¨ÈÂ¢Ä¡ ×ñÊ §¸¡¼ø 
ÌÇ¢÷ ¾Õ ÅÇ¢Â¢ü §È¸í ÌÉ¢ôÒÈ ×ÄÅø ¦ÀñÊ÷ 
¸Ç¢¾Õ ÓÂì¸õ ¦Àü§È¡÷ ¸Ê¦ºÂø ¸ÕÅ¢Â¡Á¡ø  
       -ºÀ¡À¾¢ ¨¸¦ÂÎ[4] 
• Excessive intake of bitter, astringent pungent, and acrid taste food,  
• Intake of vaatha food substance like varagu, thinai   
• Altered sleep pattern also contribute to vatha disease. 
 
¦À¡üÈ¡ Á¨ÃÂ¡ý Ò¨É¦Áö ÂÃñ¸¡ìÌõ 
¦À¡üÈ¡ Á¨ÃÂ¡ý Ò¸øÅ¦¾ý ¦À¡üÈ¡õ 
ÅÇÅ¢É¢§Ä Â¡ìÌÃõ¨À Áý¦ÉýÉ Á¢ýÉ 
ÅÇÅ¢É¢§Ä Â¡ìÌõ ÅÇ¢ 
      §¾¨ÃÂ÷ ÂÁ¸ ¦ÅñÀ¡[17] 
• Vatham is being hailed as the king, who rules the fort (Body) and enables 
the dwelling of the citizen (Uyir) in the fort. 
• Hence Theraiyar lauds Vatham as the prime force in normal state. 
 
3. HABITS
 [21]
: 
“¾¡¦ÉýÈ ¨¸ô§À¡Î ÐÅ÷ôÒÅ÷ôÒ 
º¡¾¸Á¡ö Á¢ïÍ¸¢Öõ º¨Áò¾ «ýÉõ 
¬¦ÉýÈ ¬È¢ÉÐ Òº¢ò¾Ä¡Öõ 
¬¸¡ºò §¾üÈ¿£÷ ÌÊò¾Ä¡Öõ 
Â¡¦ÉýÈ À¸ÖÈì¸õ þÃ¡Å¢Æ¢ôÒô 
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ÀðÊÉ¢§Â Á¢¸×Ú¾ø À¡Ã¦Áö¾ø 
§¾¦ÉýÈ ¦Á¡Æ¢Â¡÷ §Áø º¢ó¨¾Â¡¾ø 
º£ì¸¢ÃÁ¡ö Å¡¾ÁÐ ¦ºÉ¢ìÌó¾¡§É” 
      -ä¸¢ÓÉ¢ ¨Åò¾¢Â º¢ó¾¡Á½¢ 
• Intake of food rich in bitter ,sour and pungent in taste 
• Intake of cooled and old foods 
• Intake of rain water 
• Sleep in morning  
• Awakening in night 
• Frequency of starvation 
• Weight lifting 
• Increased sexual act  
• These are the factors  that disturbs &  increase vaatham in our body 
“ ¦ÅöÂ¢Ä¢ø ¿¼ì¨¸Â¡Öõ Á¢¸ì¾ññ£÷ ÌÊì¨¸Â¡Öõ 
¦ºöÂ¢¨Æ Á¸Ç¢É¨Ãî §º÷ó¾ÛÀ Å¢ì¨¸Â¡Öõ 
¨ÀÂ§É ¯ñ¨ÁÂ¡Öõ À¡¸ü¸¡ö ¾¢ý¨¸Â¡Öõ 
¨¾Â§Ä Å¡¾§Ã¡¸õ ºÉ¢ìÌ ¦ÁýÈÈ¢óÐ ¦¸¡û§Ç". 
       - §¾¨ÃÂ÷ Å¡¸¼õ[15] 
 The factors like, excessive walking in sun light and excessive intake of bitter 
guard , excessive sexual act also disturbs the normal functions of Vaatham. 
4. Involvement of Mukkutram, ie Vaatham, Pitham and Kabam
[3]
: 
 Viyanan and samanan  are affected in Vaatham. Resulting in pain in knee 
joints. 
 In Pitham, Sathaga pitham is affected. Resulting in painand difficulty in 
performing daily activities. 
 Santhigam is affected in Iyyam. Resulting in pain and crepitation in knee 
joints. 
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5. Characteristic features of Vaatham
 [14][15]
: 
“Å¡¾§Á ¸¾¢ò¾ §À¡Ð Å¡Ô×¦ÁØõÒí ¸¡ñÀ£÷ 
Å¡¾§Á ¸¾¢ò¾ §À¡Ð Å¡ÔÅó¾¢Îï ºýÉ¢ §¾¡„õ 
Å¡¾§Á ¸¾¢ò¾ §À¡Ð ÅøÄÎý ¦ÁÄ¢óÐ ¦¸¡øÖõ” 
     - «¸ò¾¢Â÷ º¢¸¢îº¡ ÃòÉ¡ ¾£Àõ 
 When the vaatham is increased from their normal level causes sanni and 
weight loss leads to death . 
“Å¡¾ Å£Ú «ýÉÁ¢Èí¸¡Ð ¸ÎôÒñ¼¡õ Åñ½Óñ¼¡õ 
§Á¡Ð¸ðÌ §Ã¡¸õ ÍÃÓñ¼¡ Á¢ÕÁÖÁ¡ ÓÈí¸¡¦¾ýÚõ 
µ¾Ã¢Â Å¡¾ÁÉÄ¡Ì ¿Îì¸Óñ¼¡õ ¦À¡Õû ¸ÇÂ÷ó¾ 
¾£¦¾É§Å ¿ÃõÀ¢òÐ ºóÐ¸û §¾¡Úí¸¼ ìÌó ¾¢ÉÓó¾¡§É" 
        - §¾¨ÃÂ÷ Å¡¸¼õ[15] 
 When the Vaatha humour aggravates it will produce the following signs and 
symptoms: 
• loss of appetite, 
• excruciating pain, 
• fever, 
• loss of urinary and faeces output 
• loss of sleep 
• shivering of the body, 
• nervous weakness, 
• Joint pain. 
¸¡½ôÀ¡ Å¡¾Á£È¢ø ¸¡ø¨¸¸û ¦À¡ÕòÐ §¿¡×õ 
â½ôÀ¡ Ì¼øÒÃðÎõ ÁÄºÄõ ¦À¡ÕÁ¢ì ¸ðÎõ  
°½ôÀ¡ ÌÇ¢Õí ¸¡öîºø ¯¼õ¦ÀøÄ¡õ ÌòÐÅ¡ö× 
Å£½ôÀ¡ Ì¾Á¢ÚìÌõ Å¢Â÷¨ÅÔõ §Å÷ìÌõ ¾¡§É  
 «¸ò¾¢Â÷ ¨Åò¾¢Â ¸¡Å¢Âõ 
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According to Agathiyar vaithiya Kaaviyam, the deranged vaatham produces 
increasing pain in the joints of the hands and legs ,colic pain, flatulence, constipation, 
scanty micturition, fever with rigor, generalized body pain , rectal prolapse and 
increased sweating 
SITES OF VALI 
Å¡¾õ Å¡ØÁ¢¼õ- The sites of vali  
¦¿Ç¢ó¾¢ð¼ Å¡¾ÁÀ¡ ¿ò¨¾ô ÀüÈ¢ 
¿¢¨Èó¾¢¨¼Âî §º÷óÐó¾¢ì ¸£§Æ ¿¢ýÚ 
ÌÇ¢ó¾¢ð¼ ãÄÁà ¦¼ØóÐ ¸¡Áì 
¦¸¡ÊÂ¢¨¼¨Âô ÀüÈ¢¦ÂØí Ì½ò¨¾ô À¡§Ã   
" Ì½Á¡É ¦ÅØõ¨À§Áü ¦È¡ì¨¸ ¿¡Ê 
¿¢½Á¡É ¦À¡Õò¾¢¼Óõ §Ã¡Áì ¸¡Öõ  
¿¢¨ÈÅ¡¸¢ Á¡í¸¢º¦Áø Ä¡õÀÃóÐ  
¸¡ø¸ðÊ Å¡¾¦ÁíÌí ¸ÄìÌó ¾¡§É " 
 ¨Åò¾¢Â º¾¸õ 
 According to vaithiya sathagm, vatham dwells in the following places: 
Umbilicus, rectum, faecal matters, abdomen, anus, bones, hipjoints, skin, navel 
plexus, Joints, Hair follicles and muscles. 
PROPERTIES OF VALI:      
Vaatham helps the following function in our body 
• It is the humour responsible for the function of 7 UDALKATTUGAL 
• It stimulate and accelerate 5 PULANGAL 
Natural properties of Vatham: [Ref: Noi Nadal part-1] 
1. Functioning of the ―Seven Udal Kattukal‖ uniformly 
2. Protection and strengthening of the five sensory organs. (Iymporigal) 
3. Giving briskness 
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4. Expiration and Inspiration 
5. Regulation of the ―Fourteen Physiological Reflexes‖(Vegam). 
6. Functioning of the mind, thoughts and body 
 
SYMPTOMS OF VATHAM THODAM: 
1. Body ache - ¯¼ø ÅÄ¢ 
2. Pricking pain - ÌòÐõ ¾ý¨Á ¦¸¡ñ¼ ÅÄ¢ 
3. Tearing pain - ¸¢Æ¢¾ø ¾ý¨Á ¦¸¡ñ¼ ÅÄ¢ 
4. Nerve weakness - ¿ÃõÒ §º¡÷× 
5. Mental distress - ÁÉ§º¡÷× 
6. Movements - «¨ºò¾ø 
7. Joints pain - ¸£ø¸Ç¢ø ÅÄ¢ 
8. Traumatic pain - «ÊÀð¼¨¾ô ´ò¾ ÅÄ¢ 
9. Dislocation of joints - ãðÎ Å¢Ä¸ø 
10. Weakness of organs - ¯ÚôÒ¸Ç¢ý  §º¡÷× 
11. Paralysis of limbs - ¨¸, ¸¡ø¸û Å¢ðÎ §À¡¾ø 
12. Polydypsia - «¾¢¾¡¸õ 
13. Severe pain in calf and thigh muscles -  ¦¾¡¨¼ ÁüÚõ ¸Ïì¸¡ø¸Ç¢ø 
ÅÄ¢ 
14. Bony pricking pain - ±ýÒ¸Ç¢ø Ìò¾ø ÅÄ¢ 
15. Anuria and constipation - ¿£Ã¨¼ôÒ ÁüÚõ ÁÄì¸ðÎ 
16. Unable to do flexion and extension of the limbs - ¨¸, ¸¡ø¸û ¿£ðÊ 
Á¼ì¸ þÂÄ¡¨Á 
17. All tastes to be like astringent - ±îÍ¨ÅÔõ ÐÅ÷ôÀ¡ö þÕò¾ø 
18. Excess Salivation - ¦º¡ûÙ ÅÊ¾ø  
VAATHA THEKIYIN ILLAKANAM: 
• Tall and lean body 
• Crepitations present in knee while on walking 
• Blackish white skin color 
• Thickened eyelids 
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• Whitish eyes 
• Interested in Sweet, sour, astringent foods 
• Increased sexual behavior 
• Interested in massage and hunting 
• Semi closed eyes sleep 
 
§¿¡ö ¸½¢ôÒ - DIAGNOSIS IN SIDDHA: 
Piniyari muraigal (Method of Diagnosis) is based upon three main principles, 
 Poriyal Arithal (Inspection) 
 Pulanal Arithal (Palpation) 
 Vinaathal (interrogation) 
 
1. PORIYAL ARITHAL (INSPECTION): 
PORI – SENSE ORGANS 
―Poriyal arithal‖ means examining the ―Pori‖ of the patient by the ―Pori‖ of 
thephysician for proper diagnosis.  
Pori is considered as the ―Five sense organs‖ of perception namely, 
1. Mei (Skin) 
2. Vai (Tongue) 
3. Kan (Eye) 
4. Mookku (Nose) 
5. Sevi (Ear)  
PULANAL ARITHAL (PALPATION): 
PULAN – SENSE 
 Pulanal arithal means examining the ―Pulan‖ of the patient by the Physician to 
diagnose a disease.  
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Pulan are five senses. They are, 
1. Smell  
2. Taste 
3. Vision 
4. Sensation of touch 
5. Hearing 
3. VINAATHAL (INTERROGATION): 
 Vinaathal is gathering information regarding the history of disease, its clinical 
features , major complaints, duration of illness etc., from the patient or his/her close 
relatives usefu l when the patient is not in a position to speak or in the case of a child. 
ENVAGAI THERVUGAL (EIGHT DIAGNOSTIC TOOLS): 
It is a unique method of diagnosis in Siddha system of medicine. They are clearly 
Explained by Siddhar Theraiyar; 
"¿¡Ê ŠÀÃ¢ºõ ¿¡ ¿¢Èõ ¦Á¡Æ¢ Å¢Æ¢ 
ÁÄõ ãò¾¢ÃÁ¢¨Å ÁÕòÐÅÃ¡Ô¾õ" 
      - §¾¨ÃÂ÷ 
1. Naadi (Pulse): 
“¾¢Õò¾Á¡õ Å¡¾ò§¾¡§¼ ¾£í§¸¡Î À¢ò¾õ §ºÃ¢ü 
¦À¡ÕòÐ¸û §¾¡Úõ ¦¿¡óÐ §À¡¾§Å À¢ÊìÌõ” 
       - §¿¡Â¢ý º¡Ãõ 
“Å¡ðÊÎõ §ºòÐÁò¾¢ø Åó¾¢Îõ Å¡¾Á¡¸¢ø 
¿¡ðÊÂ ¸¡ø¸û §À¡Ä ¿Ãõ¦ÀøÄ¡õ ÅÄ¢òÐ ¿¢üÌõ” 
       -«¸ò¾¢Â÷ ¿¡Ê 
¦º¡øÄ¢Â ³Âò§¾¡§¼ À¢ò¾Áí ÜÊü È¡É¡ø  
      ºÄÄ¢Âõ §À¡Äì ÌòÐõ ¨Áó¾§É ±ÖõÒõ §¾¡Öõ 
       - ¸¡Å¢Â ¿¡Ê 
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1. When piththa gets vitiation it accompany with vaatha and causes pain in 
every joints  
2. When kabha and vaatha are vitiated pain occurs in the nerves and lower 
extremities. 
3. When piththa vitiated with kapha it results in stabbing pain in bones and 
joints. 
In Keel Vaayu the following Naadies are commonly seen: 
Vaathapitham, Vaathakabam, Pithavaatham, Pithakabam, Kabavaatham. 
2. Sparism (Sensation to touch): 
In keel vaayu mild warmth noticed over the affected joint. 
3. Naa (Tongue): 
In keel vaayu no abnormality is seen in Naa. 
It is useful to diagnose the may be anemic. 
4. Niram (Colour): 
In keel vaayu no abnormality is seen in Niram. 
The skin complexion is used to diagnose the body constitution of the patient. 
5. Mozhi (Voice) 
    It constitutes high, low-pitched voice, nasal speech, hoarseness of voice 
slurring and incoherent speech etc. 
 In keel vayu no abnormatlities are seen normally. 
6. Vizhi (Eyes): 
Both motor and sensory disturbance of eye are noticed. Redness of eyes, 
paleness, excessive lacrimation, swelling, corneal ulcers, sunken eyes may be noted 
for.  In keel vayu no abnormatlities are seen normally. 
 In anaemic patients pale conjunctiva may be noted. 
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7. Malam (Faeces): 
Vatha type: Black coloured stools with constipation. 
Pitha type: Loose stools with yellowish red colour 
Kabha type: White coloured stools with mucous 
Thontha type: Stools possess some of the features of two thodams 
In  keel vaayu constipation was reported in some cases. 
8. Moothiram
[18]
: 
Neerkuri and Neikuri (Oil on urine sign) are special diagnostic methods 
regarding urine (Moothiram). 
Neerkuri and Neikkuri: 
"«ÕóÐ Á¡È¢Ã¾Óõ «Å¢§Ã¡Á¾¡ö 
« ·¸ø «Ä÷¾ø «¸¡Äçý ¾Å¢÷ó¾Æü 
ÌüÈÇ ÅÕó¾¢ ¯Èí¸¢ ¨Å¸¨È 
¬Êì ¸Äºò ¾¡Å¢§Â ¸¡Ð¦Àö 
§¾¡Õ ÓÜ÷ò¾ì ¸¨ÃÌð ÀÎ¿£Ã¢ý 
¿¢ÈìÌÈ¢ ¦¿öìÌÈ¢ ¿¢ÕÁ¢ò¾ø ¸¼§É" 
      - º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ[18] 
Prior to the day of urine examination the patient is instructed to take a 
balanced diet and quantities of food must be proportionate to his routine intake. The 
patient could have no disturbed sleep. After waking up in the morning, the first urine 
voided is collected in a clear wide mouthed glass bowel and is subjected to analysis of 
―Neerkkuri and Neikkuri‖ within one and a half an hour. 
Åó¾ ¿£÷ì¸¡¢ ±¨¼ Á½õ Ñ¨Ã ±ïº¦Äý 
¨Èó¾¢Â ÖÇ¨Å Â¨ÈÌÐ Ó¨È§Â       
- º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ[18] 
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Voided urine has the following characters 
1. Niram   - Colour 
2. Edai   - Specific Gravity 
3. Manam  - Smell 
4. Nurai   - Frothy nature 
5. Enjal   - Deposits 
Apart from these, the frequency of urination , abnormal constituents , such as 
sugar, protein, presence of blood, pus, also to be found out. 
In keel vayu patient straw coloured urine was  noticed. 
9. NEIKKURI
 [3]
: 
The process of dropped gingely oil indication 
¿¢ÈìÌÈ¢ì Ì¨Ãò¾ ¿¢ÕÁ½ ¿£¡¢ü 
º¢Èì¸ ¦Åñ¦½ö§Â¡÷ º¢ÚÐÇ¢ ¿ÎÅ¢Îò 
É¢ýÈ¾¢Å¨Ä §À¡õ ¦¿È¢Å¢Æ¢ÂÈ¢×õ 
¦ºýÈÐ Ò¸Öï ¦ºö¾¢¨Â Ô½§Ã 
    §¿¡ö ¿¡¼ø §¿¡ö Ó¾ø¿¡¼ø ¾¢ÃðÎ - À¡¸õ 1 
The collected specimen was examined by the following method. The collected 
urine specimen is kept in a glass bowel and observed under direct sunlight without 
shaking the vessel. Then drip one drop of gingely oil and observe the spreading 
pattern and concludes as follows, 
"«Ã¦ÅÉ ¿£ñËÊý « ·§¾ Å¡¾õ 
¬Æ¢§À¡ø ÀÃÅ¢ý «·§¾ À¢ò¾õ 
Óò¦¾¡òÐ ¿¢ü¸¢ý ¦Á¡Æ¢Å¦¾ý ¸À§Á 
«ÃÅ¢ø ¬Æ¢Ôõ ¬Æ¢Â¢ø «Ã×õ 
«ÃÅ¢ø ÓòÐõ ¬Æ¢Â¢ø ÓòÐõ" 
    -§¿¡ö¿¡¼ø §¿¡ö Ó¾ø ¿¡¼ø ¾¢ÃðÎ 
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When the oil drops lengthens like a snake it indicates ‗vatha Neer‘ 
When the oil drops spreads like a ring it indicates ‗pitha Neer‘ 
When the oil drops remains that of pearl it indicates‘ kaba Neer‘ 
PARUVAKAALAM (Seasonal variations):          
S.No STATE OF  KUTTRAM KAALAM 
1. Vatham thannilai  adaithal                 
Munpani kaalam, Pinpani kaalam, 
Koothir kaalam, Elavenil kaalam                                                                    
2. 
Vatham thannilai valarchi  
adaithal                 
Muthuvenil kaalam 
3. Vatham vetrunilai valarchi Kaarkaalam 
  
Vatham vitiates during Muthuvenil, i.e during summer, the environment is 
hot it leads to dryness of the body and the body loses its energy through perspiration 
and may impair the digestion. 
So, in keel vayu the disease shows its exacerbation during muthuvenil 
kaalam. 
THINAI (Geographical Distribution): 
It is divided into five types. They are, 
S. NO THINAI LAND 
AFFECTED 
HUMORS 
1. Kurinchi 
Mountain and its surroundings 
Hilly terrain 
Kabam 
2. Mullai 
Forest and its surroundings 
Forest ranges 
Pitham 
3. Marutham 
Farm land and its surroundings 
Cultivable lands 
All three humors are 
in equilibrium 
4. Neithal 
Sea shore and its adjoining areas 
Coastal belt 
Vatham 
5. Palai 
Desert and its surroundings 
Arid zone 
All three humors are 
affected. 
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¦¿ö¾É¢Ä ¦ÁÖÅ÷ô¨À ¿£í¸¡ òÈ¢ÉÁÐ 
  ¦Åö¾É¢ø §ÁòíÌ Å£¼¡Ìõ - ¦¿¡ö¾£ý 
ÁÕíÌ¼¨Ä Óì¸¡ì¸¢ ÅøÖÚô¨ÀÅ£ìÌõ 
  ¸ÕíÌ¼¨Äì ¸£Æ¢È¢ìÌí ¸¡ñ. 
       -À¾¡÷ò¾ Ì½ º¢ó¾¡Á½¢ 
Geographical distribution plays a vital role in altering Mukkutrams. According 
to Siddha, vatha diseases are predominant in Mullai and Neithal Thinai 
UDAL KATTUGAL
 [3]
: 
Our body consists of seven udal kattukal. 
SL. 
No 
UDAL 
KATTUGAL 
FUNCTIONS INCREASED 
CONDITIONS 
DECREASED 
CONDITIONS 
1 SAARAM It gives strength 
to the body and 
mind. 
Loss of appetite, 
excessive 
salivation,diminished 
activity, heaviness, 
pallor, cold, decreased 
physical constituents, 
dyspnoea, flatulence, 
cough, excessive sleep.            
Tiredness,dryness of 
skin, Laziness, loss 
of weight, lassitude, 
and irritability while 
hearing heavy noise. 
2 SENEER Saaram after 
absorption is 
converted into 
senneer.  
Responsible for 
knowledge, 
strength, boldness 
and healthy 
complexion. 
Boils and tumours in 
different                                
Parts of the body, 
Spleenomegaly, 
Pricking pain, increased 
blood   Pressure, reddish 
eye and skin, jaundice, 
leprosy, haematuria etc.                           
Affinity to sour and 
cold food, nervous  
debility, dryness , 
pallor.  
3 OON Gives structure 
and shape to the 
body and is 
responsible for 
the movements of 
the body. 
Tubercular adenitis, 
Tumours or extra 
growth around  the 
neck,  cheeks, abdomen, 
thigh, genitalia. 
Lethargic sense 
organs, pain in the 
joints, muscle 
wasting in 
mandibular region, 
gluteal region, penis, 
thighs. 
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4 KOZHUPU Lubricates the 
organs on its own 
works. 
 Identical feature of 
increased flesh, 
tiredness, dyspnoea on 
exertion, extra 
musculature in gluteal 
region, external 
genetalia, chest, 
abdomen thighs  
 Loins Pain, 
spleenomegaly, 
emaciation. 
5 ENBU Protects the vital 
organs and used 
for movements 
and nominates the 
body structure. 
 Excessive ossification 
and dentition 
Joint pain, falling of 
teeth, falling and 
splitting of hairs and 
nails.                                          
6 MOOLAI Present inside the 
bones and it gives 
strength and 
maintains the 
normal Condition 
of the bone. 
 Heaviness of the body 
and  eyes, swollen inter 
phalangeal joints, 
oliguria  and non 
healing ulcers. 
Osteoporosis, 
Blurred vision. 
  
7 SUKKILAM/ 
SURONITHAM 
Responsible for 
the reproductive 
function of 
species. 
 
 Increased sexual 
activity and                              
 Signs identical to 
urinary calculi                              
Dribbling of 
sukkilam/ 
suronitham or 
senneer during 
coitus, pricking pain 
in the testis, 
inflammed and 
contused external 
genitalia. 
 
In keel vaayu,  
Saaram, Kozhuppu, Moolai and Enbu thathukkal are commonly affected. 
• Saaram: Weakness, pain in knee joints 
• Kozhuppu : Morning stiffness occurs in affected knee joints 
• Enbu  : Pain occurring in affected knee joints, crepitations present 
• Moolai  : Inflammation, degeneration, swelling etc 
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MUKKUTRAM: 
Human body is influenced by Mukkutram ie Vaatham, Pitham and Kabam. 
They are responsible for normal physiological conditions of the body.  
VAATHAM is mainly responsible for proper loco-motor functions. 
 Bones and joints are considered to be the main location of vaatha. 
In keel vaayu  
The vaatha kutram is mainly affected followed by Pitham and Kabam. This 
produces the following signs and symptoms, 
• Deranged viyanan leads to pain and difficulty in movements. Deranged 
abanan leads to constipation. 
• Inflammatory changes of the joints, redness and warmth are developed due 
to deranged pitham.  
• Sathaga pitham gets affected hindering the loco motor functions  
• Along with vaatham, kabam is also deranged, santhikam is affected and 
this leads to Abnormality in joint movements 
• Erosions of bone margin increased secretion of synovial fluid due to the 
deranged fluid developed by deranged kabam. 
 
1. In keel vaayu Abanan is affected and so constipation is produced. 
2. Viyanan is affected it renders difficulty in movements of the knee joints. 
3. Samanan is also affected because disturbed state of other Vaayu. 
PITHAM: 
In keel vaayu, Sathaga Pitham affected and produces difficulty in walking, 
climbing upstairs, squatting and sitting postures. 
KABAM: 
Kaba kutram stabilizes and maintains the movements of the joints and gives 
lubrications to all movements. 
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In keel vaayu Santhigam is affected and produce difficulty in movements of 
the knee joints. 
NOI KANIPPU VIVATHAM (DIFFERENTIAL DIAGNOSIS) 
[4]
: 
 Keel vaayu (OA-KNEE) is differentiated from the followings diseases, 
1. VALI KEEL VAAYU: 
 It is characterized by excruciating pain and swelling involving knee joints, hip 
joints, elbow joints, shoulder joints and associated with systemic disturbances like 
dryness of mouth, pyrexia, headache, palpitation, constipation and sweating. In 
advanced cases it may affect the heart and produce “Thamaraga vaayu”. 
2. IYA KEEL VAAYU: 
It is characterized by severe pain in the joints associated with emaciation of 
the body, anorexia, insomnia, cough, hiccough, vomiting, anaemia and dropsy. The 
common sites are spinal cord, hip joints and knee joints. 
.3.  VALI IYA KEEL VAAYU:  
It is characterized by pain in the joints associated with effusions of joint fluid 
and swelling, restricted joint movements, pyrexia, fainting, insomnia, especially in 
knee joint asymmetrically, lymphadenopathy, generalized malaise, atrophy of the 
affected limb etc.    The affected joint looks like “Fox’s Head”. 
LINE OF TREATMENT 
         In Siddha system the main aim of the treatment is to cure Udarpini (due to 
Mukkuttram) and Manapini (due to changes in Mukkunam). Treatment is not only for 
perfect healing but also for the prevention and rejuvenation. 
       It is essential to know the disease, the aetiology, the nature of the patient, severity 
of the illness, the seasons and the time of occurrence must be observed clearly. 
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Line of treatment is as follows: 
1. Neekkam (Treatment) 
2. Niraivu (Rejuvenation) 
3. Kaapu (Prevention) 
Thiruvalluvar describes the duty of the physician, i.e. study the disease, aetiology, 
seek subsiding ways and do what is proper and effective. 
"§¿¡ö ¿¡Ê §¿¡ö Ó¾ø ¿¡Ê «Ð ¾½¢ìÌõ 
Å¡ö ¿¡Ê Å¡öôÀî ¦ºÂø" 
"¯üÈ¡ÉÇ×õ À¢½¢ÂÇ×í ¸¡ÄÓõ 
¸üÈ¡ý ¸Õ¾¢î ¦ºÂø" 
       - ¾¢ÕìÌÈû. 
1) NEEKKAM (Treatment in Siddha): 
 The aim of Neekkam is based on to bring the deranged Thodams to normal 
equilibrium state.To treat the patient with internal medicine and external medicine. 
  Siddha system of Medicine is based on Mukkutra Theory and hence the 
treatment is mainly aimed to bring the three thodams to equilibrium state and thereby 
restoring the physiological condition of the seven Thathus. 
 The three Thodams organise, regularise and integrate the body structure and 
their functions. They are always kept in a state of balance by thought, word, deed and 
food. Any imbalance will lead to disease. The imbalanced thodams are balanced by 
administrating purgatives or emetics or application of Anjanam (application on eyes) 
and followed by the appropriate systemic therapy by giving Siddha drugs.  
It mentioned as below: 
"Å¢§ÃºÉò¾¡ø Å¡¾ó ¾¡Øõ" 
"ÅÁÉò¾¡ø À¢ò¾õ ¾¡Øõ" 
"¿º¢Â «ïºÉò¾¡ø ¸Àõ ¾¡Øõ"                  
                              - º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ 
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 The purgatives should be given before starting the trial to normalize the 
deranged Thodams to normal. 
 In this study the purgation is induced by giving Agasthiyar kulambu - 130 mg 
with hot water in early morning in empty stomach on the first day. 
 Then the next day onwards the trial drugs Pachaikarpoora vadagam – 1  twice 
a day given with hot water after food. Vaeppa Ennai – External application. 
2) NIRAIVU (Rejuvenation): 
The word literally means the power of securing the body from the effect of 
age.According to Siddhars science rejuvenation does not necessarily mean restoring 
the old to youth for it may simply mean the maintenance of youth without reaching 
the old age. 
So rejuvenation is a means for prolonging life & forms a part of immortality. 
       T.V.Sambasivam pillai dict. 
(Physical, psychological, social and economic rehabilitation and reassurance of 
Individuals are known as Niraivu). 
3. KAPPU (PREVENTION): 
The prevention methods for Azal keel vaayu are as follows: 
• Control the body weight by diet and exercise. 
• Modify the nature of work which gives stress to a particular joint. 
• e.g. - Avoid prolonged standing and long distance walking. 
• Avoid to intake excess sour, astringent and bitter tasted foods. 
4) DIETARY RESTRICTIONS: 
In siddha system of medicine the importance of dietary habits also 
emphasiszed for the diseases management and prevention. 
“ÁÕó¦¾É §Åñ¼¡Å¡õ Â¡ì¨¸ìÌ «Õó¾¢ÂÐ 
       «üÈÐ §À¡üÈ¢ ¯½¢ý”.      - ¾¢ÕìÌÈû 
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In diseased condition diet restrictions or paththiyam are strictly followed to 
increase the effectiveness of medicine, and to reducing the severity of diseases. This 
is given in the following verse, 
“Àò¾¢Âò¾¢É¡§Ä ÀÄý ¯ñ¼¡Ìõ ÁÕóÐ 
Àò¾¢Âí¸û §À¡É¡ø ÀÄý§À¡Ìõ - Àò¾¢Âò¾¢ø 
Àò¾¢Â§Á ¦ÅüÈ¢¾Õõ ÀñÊ¾÷ìÌ ¬¾Ä¢É¡ø 
Àò¾¢Â§Á ¯ò¾¢¦ÂýÚ À¡÷” 
     - §¾¨ÃÂ÷ ¦ÅñÀ¡. 
þîº¡ Àò¾¢Âò¾¢ø ¿£ìÌõ ¦À¡Õð¸û: 
"¸ÎÌ ¿üÈ¢Äò ¦¾ñ¨½ö ÜúÀ¡ñ¼í¸û ¸¼¨Ä 
ÅÕÅ¾¡¸¢Â ¦¾íÌÁ¡ ÅÕì¨¸ ¿ü¸¡Âõ 
ÁÊÅ¢Ä¡¾ ¦ÅûÙûÇ¢¦¸¡û Ò¨¸Â¢¨Ä ÁÐ¦Àñ 
þ¼Ú À¡¸§Ä¡ ¼¸ò¾¢ ¿£ì¸¢¼Ä¢îº¡ Àò¾¢Âõ" 
     - º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ 
¸ÎÌ, ±û¦¿ö, ¸øÂ¡½âº½¢ì¸¡ö, ¸û, ¸¼¨Ä, §¾í¸¡ö, Á¡í¸¡ö, 
ÀÄ¡, ¸¡Âõ, ¯ûÇ¢ôâñÎ, ¦¸¡û, Ò¨¸Â¢¨Ä, ¦Àñ¸û §º÷ì¨¸, À¡¸ø, 
«¸ò¾¢ þ¨Å¸¨Ç þîº¡ Àò¾¢Âò¾¢ø ¿£ì¸ §ÅñÎõ. 
"ÒÇ¢ÐÅ÷ Å¢ïÍõ ¸È¢Â¡ø âÃ¢ìÌõ Å¡¾õ" 
     - §¿¡ö ¿¡¼ø §¿¡ö Ó¾ø ¿¡¼ø ¾¢ÃðÎ 
ÁÕòÐÅ «È¢×¨Ã: 
ÒÇ¢ôÒ, ÐÅ÷ôÒ Í¨ÅÔûÇ ¯½× Å¨¸¸¨Ç ¿£ì¸ §ÅñÎõ 
®ÃÁ¢øÄ¡ò ¾¨ÃÂ¢Öõ, ÀÎì¨¸Â¢Öõ ÀÎò¾ø §ÅñÎõ, 
ÌÇ¢÷ ¸¡üÚ ÀÎõÀÊÂ¡É þ¼ò¾¢ø þÕôÀ¨¾ò ¾Å¢÷ì¸×õ. 
¯¼ø «¾¢¸ ±¨¼ þÕôÀ¢ý ±¨¼¨Âì Ì¨Èì¸ §ÅñÎõ. 
«¾¢¸  àÃõ ¿¼ò¾ø, «¾¢¸ §¿Ãõ ¿¢üÈø ¾Å¢÷ì¸×õ. 
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MODERN ASPECTS  
 
ANATOMY OF JOINTS: 
[5][11][24][25][26][27]
 
 Joints can be classified as synovial, fibrous, or combination joints, based on 
the presence or absence of a synovial membrane and the amount of motion that occurs 
in the joint. Normal synovial joints allow a significant amount of motion along their 
extremely smooth articular surface. The joints are composed of the following: 
 Articular cartilage 
 Subchondral bone 
 Synovial membrane 
 Synovial fluid 
 Joint capsule. 
 
 The normal articular surface of synovial joints consists of articular cartilage 
(Composed of chondrocytes) surrounded by an extracellular matrix that includes 
various macromolecules, most importantly proteoglycans and collagen. The cartilage 
protects the underlying subchondral bone by distributing large loads, maintaining low 
contact stresses, and reducing friction at the joint. 
 Synovial fluid is formed through a serum ultra filtration process by cells that 
form the synovial membrane (synoviocytes). Synovial cells also manufacture the 
major protein component of synovial fluid, hyaluronic acid (also known as 
hyaluronate). Synovial fluid supplies nutrients to the avascular articular cartilage; it 
also provides the viscosity needed to absorb shock from slow movements, as well as 
the elasticity required to absorb shock from rapid movements. 
 
ANATOMY OF THE KNEE JOINT 
 
Introduction: 
The knee joint is the largest joint in the body, consisting of four bones and an 
extensive network of ligaments and muscles. Injuries to the knee joint are amongst the 
most common in sporting activities and understanding the anatomy of the joint is 
fundamental in understanding any subsequent pathology. 
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Bones of the knee joint: 
 The knee is made up of four main bones. The femur (thigh bone), the tibia 
(shin bone), fibula (outer shin bone) and patella (kneecap). The main movements of 
the knee joint occur between the femur, patella and tibia. Each are covered in articular 
cartilage which is an extremely hard, smooth substance designed to decrease the 
frictional forces as movements occurs between the bones. The patella lies in an 
indentation at the lower end of the femur known as the inter-condylar groove. At the 
outer surface of the tibia lies the fibula, a long thin bone that travels right down to the 
ankle joint. 
 
 
The capsule: 
 The knee joint capsule is a thick ligamentous structure that surrounds the 
entire knee. Inside this capsule is a specialized membrane known as the synovial 
membrane which provides nourishment to all the surrounding structures. Other 
structures include the infrapatellar fat pad and bursa which function as cushions to 
exterior forces on the knee. The capsule itself is strengthened by the surrounding 
ligaments. 
 
Ligaments of the knee joint: 
The stability of the knee owes greatly to the presence of its ligaments. Each 
has a particular function in helping to maintain optimal knee stability in a variety of 
different positions. 
 
Menisci (knee cartilage): 
 Each knee joints has two crescent shaped cartilage menisci. These lie on the 
medial and lateral edges of the upper surface of the tibia bone. They are essential 
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components, acting as shock absorbers for the knee as well as allowing for correct 
weight distribution between the tibia and the femur. 
 
LIGAMENTS AND MENISCI OF KNEE JOINTS 
 
 
Muscle groups surrounding the knee joint: 
 The two main muscle groups of the knee joint are the quadriceps and the 
hamstrings. Both play a vital role in moving and stabilizing the knee joint. 
 
Quadriceps muscle: 
 The quadriceps muscle group is made up of four different individual muscles 
which join together forming the quadriceps tendon. This thick tendon connects the 
muscle to the patella which in turn connects to the tibia via the patellar tendon. 
Contraction of the quadriceps, pull the patella upwards and leads to knee extension. 
 
Hamstrings muscle: 
 The Hamstrings muscle function in flexing the knee joint as well as providing 
Stability on either side of the joint line. 
  
29 
 
MUSCLES AROUND THE KNEE JOINT 
AP-VIEW 
 
 
 
LATERAL VIEW 
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OSTEO ARTHRITIS (OA) 
 
INTRODUCTION: 
 OA is a degenerative joint disease involving the cartilage and many of its 
surrounding tissues. In addition to damage and loss of articular cartilage, there is 
remodelling of subarticular bone, osteophyte formation, ligamentous laxity, 
weakening of periarticular muscles and in some cases, synovial inflammation.  
 These changes may occur as a result of an imbalance in the equilibrium 
between the breakdown and repair of joint tissue. Primary symptoms of OA include 
joint pain, stiffness and limitation of movement. Disease progression is usually slow 
but can ultimately lead to joint failure with pain and disability. Osteoarthritis is 
abbreviated as OA or referred to as degenerative arthritis or degenerative joint disease 
(DJD). 
 
EPIDEMIOLOGY: 
 
International statistics: 
OA may develop in any joint, but most commonly affects the knees, hips, 
hands, facet joints and feet. The prevalence of osteoarthritis differs among different 
ethnic groups. The disorder is more prevalent in Native Americans than in the general 
population. 
In 2005, it was estimated that over 26 million people in the US had some form 
of OA. The prevalence of OA, however, varies greatly depending on the definition 
used, age, sex and geographical area studied. 
  Knee OA increases with age, and women have higher rates than men, 
especially after the age of 50 years. 
  The age- and sex-standardized incidence rate from the Fallon Community 
Health Plan in Massachusetts (USA) was highest for knee OA 240/100,000 person-
years prevalence was 1.6 per 1000 per year in men and women respectively and for 
knee OA. 
Osteoarthritis of the hip is seen less frequently in Chinese patients from Hong 
Kong than in age-matched white populations. In persons older than 65 years, 
osteoarthritis is more common in whites than in blacks. Knee osteoarthritis appears to 
be more common in black women than in other groups. In India knee arthritis is more 
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common in females than males and it is the most frequent joint disease with 
prevalence of 22 - 39 %. 
 
Age- and sex-related prevalence: 
 `Primary osteoarthritis is a common disorder of the elderly, and patients are 
often asymptomatic. Approximately 80-90% of individuals older than 65 years have 
evidence of primary osteoarthritis. Patients with symptoms usually do not notice them 
until after age 50 years. The prevalence of the disease increases dramatically among 
persons over age 50, likely because of age-related alterations in collagen and 
proteoglycans that decrease the tensile strength of the joint cartilage and because of a 
diminished nutrient supply to the cartilage. 
 In individuals older than age 55 years, the prevalence of osteoarthritis is 
higher among women than men. Knee involvement is more common in women, with 
female-to-male ratios varying between 1.5:1 and 4:1. 
 Prevalence of knee OA in those aged 55 and above was 15.6% in men and 
30.5% in women .Women are especially susceptible to osteoarthritis in the distal 
interphalangeal joints joints of the fingers.  
 At age 18-24 years, 7% of men and 2% of women show signs of osteoarthritis 
in the Hands. At the age 45- 55 and above was 15.6% in men and 30.5% in women 
and 23% show signs of osteoarthritis in the hip.  
 At age 65-74 years, 39% of men and women 24 show signs of osteoarthritis in 
the knee and 23% show signs of osteoarthritis in the hip.  
 At age 75-79 years, approximately 100% of men and women show some signs 
of osteoarthritis. 
 
CLASSIFICATIONS: 
It could be divided into 2 types 
1. Primary or idiopathic osteoarthritis 
2. Secondary osteoarthritis 
 
1. Primary or idiopathic osteoarthritis: 
It is due to wear and tear changes occurring in old age in which the weight 
bearing 
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joints like the hips and knees are more commonly affected. It is uncommon in non-
weight bearing joints like the shoulder and elbow. Obesity is a predisposing factor. 
 
2. Secondary osteoarthritis: 
It is due to an abnormal wear and tear in a joint, caused by mechanical 
incongruity of 
the articular surfaces. This incongruity is due to the 
 Mal-union of fractures involving the articular surfaces of tibia, femur or 
patella 
 Loose bodies in the joint 
 Malalignment of the bones due to deformity like genu valgum or genu varum. 
 
SITES OF PRIMARY OSTEOARTHRITIS: 
Common sites: 
 Apophyseal joint of the cervical spine 
 Thoraco lumbar spine 
 First carpometacarpal joint 
 Distal interphalangeal joint 
 Patello-femoral joint 
 Tibio-femoral joint 
 First metatarsalphalangeal joint 
 
Less common sites: 
 Acromio clavicular joint 
 Hip joint 
 
Uncommon sites: 
 Shoulder joint 
 Elbow joint 
 Wrist joint 
 Metaphalangeal joint 
 Ankle joint 
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DIFFERENCE BETWEEN PRIMARY OA AND SECONDARY OA 
 
 
PRIMARY OSTEOARTHRITIS SECONDARY OSTEOARTHRITIS 
Usually limited to one or a small number of 
joints. 
May be limited to a small number of joints in 
injury related or may be in joints throughout 
body, if disease related 
It is seen in spine, hips, knees, thumbs, and top 
two sets of finger joints 
It is seen in hips, ankles, shoulders, wrists, 
and the middle set of finger joints. 
No specific inflammatory or metabolic 
condition known to be associated with arthritis 
is Absent. 
 Condition that cause damage to 
cartilage are Absent such as - 
Inherited disease of iron, calcium or 
copper storage such as 
hemochromatosis, 
 Hyperparathyroidism or Wilson‘s 
disease. 
 Neurologic disorder that result in the 
loss of nerve 
 Function. 
 Congenital disease that cause an 
imbalance in the 
 Joints. 
No history of specific injury or Trauma. History of injury to joints, such as fractures 
and tears or history of trauma to joints, such 
as Repetitive heavy lifting. 
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DIFFERENCE BETWEEN HEALTH KNEE AND ARTHRITIC KNEE 
 
 
 
STAGES OF OSTEOARTHRITIS OF THE KNEE: 
Osteoarthritis (OA) is divided into five stages 0 is assigned to a normal, 
healthy knee. 
   
The highest stage, 4, is assigned to severe OA.  
 
1. Stage 0 OA is classified as ―normal‖ knee health.  
2. A person with Stage 1 OA is showing very minor bone spur growth. A  person 
with Stage 1 OA is not experiencing any pain or discomfort as a result of the 
very minor wear on the components of the joint. 
3. Stage 2 OA of the knee is considered a ―mild‖ stage of the condition. X-rays 
of knee joints in this stage will reveal greater bone spur growth, but the 
cartilage likely remains at a healthy size—the space between the bones is 
normal, and the bones are not rubbing or scraping one another.  
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Synovial fluid is also typically still present at sufficient levels for normal joint 
motion. However, this is the stage where people may first begin experiencing 
symptoms—pain after a long day of walking or running, greater stiffness in 
the joint when it‘s not used for several hours, tenderness when kneeling or 
bending. 
4. Stage 3 OA is classified as ―moderate‖ OA. The cartilage between bones is 
showing obvious damage, and the space between the bones is narrowing.  
People with stage 3 OA of the knee are likely experiencing frequent pain when 
walking, running, bending, or kneeling.  
They also may experience joint stiffness after sitting for long periods of time 
or when waking up in the morning. Joint swelling may be present after 
extended periods of motion, too. 
5. Stage 4 OA is considered ―severe.‖ People in Stage 4 OA of the knee 
experience great pain and discomfort when walking or moving the joint. 
That‘s because the joint space between bones is dramatically reduced—the 
cartilage is almost completely gone, leaving the joint stiff and possibly 
immobile. The synovial fluid is decreased dramatically, and it no longer helps 
reduce the friction among the moving parts of a joint. 
 
STAGES OF OSTEO ARTHRITIS 
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PATHOPHYSIOLOGY 
  
Primary and secondary osteoarthritis are not separable on a pathologic basis, 
though bilateral symmetry is often seen in cases of primary osteoarthritis, particularly 
when the hands are affected 
 Traditionally, osteoarthritis was thought to affect primarily the articular 
cartilage of synovial joints; however, pathophysiologic changes are also known to 
occur in the synovial fluid, as well as in the underlying (subchondral) bone, the 
overlying joint capsule, and other joint tissues (see Workup).  
 Although osteoarthritis has been classified as a noninflammatory arthritis, 
increasing evidence has shown that inflammation occurs as cytokines and 
metalloproteinases are released into the joint. These agents are involved in the 
excessive matrix degradation that characterizes cartilage degeneration in 
osteoarthritis.[ Therefore, it is no longer appropriate to use the term degenerative joint 
disease when referring to osteoarthritis. 
 In early osteoarthritis, swelling of the cartilage usually occurs, because of the 
increased synthesis of proteoglycans; this reflects an effort by the chondrocytes to 
repair cartilage damage. This stage may last for years or decades and is characterized 
by hypertrophic repair of the articular cartilage. 
 As osteoarthritis progresses, however, the level of proteoglycans eventually 
drops very low, causing the cartilage to soften and lose elasticity and thereby further 
compromising joint surface integrity. Microscopically, flaking and fibrillations 
(vertical clefts) develop along the normally smooth articular cartilage on the surface 
of an osteoarthritic joint. Over time, the loss of cartilage results in loss of joint space. 
 In major weight-bearing joints of persons with osteoarthritis, a greater loss of 
joint space occurs at those areas experiencing the highest loads. This effect contrasts 
with that of inflammatory arthritides, in which uniform joint-space narrowing is the 
rule. 
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In the osteoarthritic knee, for example, the greatest loss of joint space is 
commonly seen in the medial femorotibial compartment, though the lateral 
femorotibial compartment and patellofemoral compartment may also be affected. 
Collapse of the medial or lateral compartments may result in varus or valgus 
deformities, respectively. 
 Erosion of the damaged cartilage in osteoarthritic joint progresses until the 
underlying bone is exposed. Bone denuded of its protective cartilage continues to 
articulate with the opposing surface. Eventually, the increasing stresses exceed the 
biomechanical yield strength of the bone. The subchondral bone responds with 
vascular invasion and increased cellularity, becoming thickened and dense (a process 
known as eburnation) at areas of pressure. 
 The traumatized subchondral bone may also undergo cystic degeneration, 
which is attributable either to osseous necrosis secondary to chronic impaction or to 
the intrusion of synovial fluid. Osteoarthritic cysts are also referred to as subchondral 
cysts, pseudocysts, or geodes (the preferred European term) and may range from 2 to 
20 mm in diameter. Osteoarthritic cysts in the acetabulum (see the image below) are 
termed Egger cysts. 
 At areas along the articular margin, vascularization of subchondral marrow, 
osseous metaplasia of synovial connective tissue and ossifying cartilaginous 
protrusions lead to irregular outgrowth of new bone (osteophytes). Fragmentation of 
these osteophytes or of the articular cartilage itself results in the presence of intra-
articular loose bodies (joint mice). 
 Along with joint damage, osteoarthritis may also lead to pathophysiologic 
changes in associated ligaments and the neuromuscular apparatus. For example, 
lateral collateral ligament complex abnormalities are common in knee osteoarthritis. 
 
AETIOLOGY: 
PRIMARY CAUSE OF OSTEOARTHRITIS: 
Though exact cause is not known, the following factors are suspected to play an 
important role in the causation of primary osteoarthritis  
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1) Endocrine 
2) Post Traumatic 
3) Inflammatory joint disease 
4) Metabolic 
5) Congenital or developmental 
6) Genetic 
7) Neuropathic  and others 
1. ENDOCRINE:  
 People with Diabetes may be prone to osteoarthritis. Other endocrine 
problems also may promote development, including Acromegaly, Hypothyroidism, 
Hyper parathyroidism and Obesity. 
2. POST TRAUMATIC:  
 Traumatic causes can be further divided into macro trauma or micro trauma. 
An example of macro trauma is an injury to the joint such as bone break causing the 
bones to line up improperly (mal alignment), lose of stability or damage cartilage. 
Micro trauma may occur over time (chronically). An example of this would be 
repetitive movements or the overuse noted in several occupations. 
3. INFLAMMATORY JOINT DISEASE: 
 This category would include infected joints, chronic gouty arthritis and 
rheumatoid disease. 
 4. METABOLIC: 
 Disease causing errors of metabolism may cause osteoarthritis. Examples 
include Paget‘s disease and Wilson‘s disease. 
5. CONGENITAL OR DEVELOPMENTAL: 
 Abnormal anatomy such as unequal length of legs may be a cause of 
osteoarthritis. 
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6. GENETIC: 
 A genetic defect may promote breakdown of the protective architecture of 
cartilage. Examples include collagen disturbances such as Ehlers- Danlos Syndrome. 
7.  NEUROPATHIC: 
 Diseases such as Diabetes can cause nerve problems. It may affect the the 
Joints and limbs.  
8. OTHERS: 
 Nutritional problems may cause osteoarthritis. Other disease such as 
haemophilia and sickle cell anaemia are further examples. 
SECONDARY CAUSES OF OSTEO ARTHRITIS: 
The causes for secondary osteoarthritis of the knee are as follows: 
• Obesity 
• Valgus and varus deformities of the knee. 
• Intra – articular fractures of the knee, etc. 
• Rheumatoid arthritis, infection, trauma, TB, etc. 
• Hyper parathyroidism. 
• Haemophilia. 
• Syringomyelia  
• Overuse of intra- articular steroid therapy. 
  It is generally observed that secondary osteoarthritis occurs in the younger 
age groups and is more severe than the primary. Apart from all the features of 
osteoarthritis, secondary osteoarthritis has the features of the corresponding 
aetiological condition. 
RISK FACTORS 
Factors that increase your risk of osteoarthritis include: 
• Older age. The risk of osteoarthritis increases with age. 
• Sex. Women are more likely to develop osteoarthritis, though it 
isn't clear why. 
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• Bone deformities. Some people are born with malformed joints or 
defective cartilage, which can increase the risk of osteoarthritis. 
• Joint injuries. Injuries, such as those that occur when playing sports 
or from an accident, may increase the risk of osteoarthritis. 
• Obesity. Carrying more body weight puts added stress on your 
weight-bearing joints, such as your knees. 
• Certain occupations. If your job includes tasks that place repetitive 
stress on a particular joint, that joint may eventually develop 
osteoarthritis. 
• Other diseases. Having diabetes, underactive thyroid, gout or 
Paget's disease of bone can increase your risk of developing 
osteoarthritis. 
 
SIGNS AND SYMPTOMS: 
 Osteoarthritis symptoms often develop slowly and worsen over time. Signs 
and symptoms of osteoarthritis include: 
• Pain. Your joint may hurt during or after movement. 
• Tenderness. Your joint may feel tender when you apply light 
pressure to it. 
• Stiffness. Joint stiffness may be most noticeable when you wake up 
in the morning or after a period of inactivity. 
• Loss of flexibility. You may not be able to move your joint through 
its full range of motion. 
• Grating sensation. You may hear or feel a grating sensation when 
you use the joint. 
• Bone spurs. These extra bits of bone, which feel like hard lumps, 
may form around the affected joint. 
. 
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PAIN MECHANISMS IN OSTEOARTHRITIS 
 Pain, the main presenting symptom of osteoarthritis, is presumed to arise from 
a combination of mechanisms, including the following: 
• Osteophytic periosteal elevation 
• Vascular congestion of subchondral bone, leading to increased 
intraosseous pressure 
• Synovitis with activation of synovial membrane nociceptors 
• Fatigue in muscles that cross the joint 
• Overall joint contracture 
• Joint effusion and stretching of the joint capsule 
• Torn menisci 
• Inflammation of periarticular bursae 
• Periarticular muscle spasm 
• Psychological factors 
• Crepitus (a rough or crunchy sensation) 
STIFFNESS: 
 Stiffness of the affected joint is often noticed first thing in the morning, and 
after resting. Stiffness during rest (gelling) may develop, with morning joint stiffness 
usually lasting for less than 30 minutes. 
SWELLING: 
 Swelling, which is sometimes warm to touch, may be noticeable in an arthritic 
joint. 
DEFORMITY: 
 Deformity can occur with osteoarthritis due to bone growths and cartilage loss. 
Bone growths in the end joints of the fingers are called Heberden‘s nodes. Bouchard‘s 
nodes are bone growths in the middle joints of the fingers. Degeneration of knee 
cartilage can result in the outward curvature of knees (bow- leggedness). 
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PHYSICAL EXAMINATION: 
 Physical examination findings in patients with the disease are mostly limited 
to the affected joints.  
 A deep, achy joint pain, presumably arising from a combination of 
mechanisms, is the main  symptom of osteoarthritis. Also, reduced range of motion 
and crepitus are frequently present .  
 Malalignment with a bony enlargement (depending on the disease‘s severity) 
may occur. Most cases of osteoarthritis do not involve erythema or warmth over the 
affected joints.  
 However, an effusion may be absent. Limitation of joint motion or muscle 
atrophy around a more severely affected joint may occur. Heberden nodes, which are 
absent palpable osteophytes in the distal interphalangeal joints, are characteristic in 
women but not in men. Inflammatory changes are typically absent or at least not 
pronounced. 
DIAGNOSIS: 
 There is no single sign, symptom or test result that allows a definitive 
diagnosis of osteoarthritis. Instead the diagnosis is based on a consideration of several 
factors, including the presence of the characteristic signs and symptoms of 
osteoarthritis, physical examination and the results of laboratory tests and x-rays. 
PROGRESSION OF OSTEOARTHRITIS: 
 The etiopathogenesis of osteoarthritis has been divided into 3 stages. 
1. Proteolytic breakdown of the cartilage matrix occurs. 
2. The fibrillation and erosion of the cartilage surface, with a subsequent release 
of proteoglycan and collagen fragments into the synovial fluid. 
3. The breakdown products of cartilage induce a chronic inflammatory response 
in the synovium. 
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PROGNOSIS: 
 The prognosis of osteoarthritis depends on the joints involved and the severity 
of the condition. A several clinical features associated with more rapid knee 
osteoarthritis (OA) progression, these include age, body mass index, varus deformity, 
and multiple involved joints, and their presence may help identify those more likely to 
have knee OA progression. The prognosis is good for patients with osteoarthritis who 
have undergone joint replacement, with success rates for hip and knee arthroplasty 
being generally more than 90%. Younger and more active patients will require 
revisions, whereas the majority of older patients will not. 
DIAGNOSTIC CRITERIA: 
Formal criteria helpful for diagnosis of osteoarthritis in synovial joints: 
• Age greater than 60 years. 
• Pain and swelling in knee joint 
• Morning stiffness lasting less than 30 minutes. 
• Crackling sensation (crepitus) present in knee joint. 
• Joint- line or periarticular tenderness.  
• Bony swelling (osteophyte) around joint margins. 
• Restricted joint movements 
INVESTIGATIONS: 
a. X - Ray 
 Radiological features: The earliest change seen is the asymmetrical narrowing 
of the joint space and subchondral sclerosis in the medial compartment of the joint. 
Later, osteophytes are seen in the periphery of the articular surfaces of the femur, tibia 
and patella. 
b. Arthroscopic Examination 
 It allows direct inspection and visualization of the damaged joint surface. 
c. Synovial fluid Analysis 
 Shows non-inflammatory picture. 
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d. Bone scan  
e. CT 
f. MRI. 
COMPLICATIONS OF OSTEOARTHRITIS: 
The major complications of osteoarthritis of knee 
• Joint deformities 
• Subluxation  
• Ankylosis  
• Intra- articular loose bodies 
Life style effects include 
• Depression 
• Anxiety 
• Feelings of helplessness 
• Limitation  of  daily activities 
• Job limitations 
 
 
 
 
 
 
 
 
 
 
   
Materials & Methods 
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4. MATERIALS AND METHODS 
 
STUDY DESIGN & CONDUCT OF STUDY: 
 
• STUDY TYPE: An open clinical trial 
• STUDY PLACE: OPD & IPD of Ayothidoss Pandithar Hospital, National 
Institute of Siddha, Tambaram Sanatorium, Chennai-47. 
• STUDY PERIOD:12 Months 
• SAMPLE SIZE:40 Patients  
•  
PREPARATION AND PROPERTIES OF TRIAL DRUGS 
 
STANDARD OPERATING PROCEDURE:  
SOURCE OF TRIAL MEDICINE: 
 
 The required raw drugs for the preparation of POORA PARPAM (internal) and 
NATHAICHOORI ENNAI(external)  were  purchased from a well reputed country 
shop and the raw drugs will be authenticated in concern department ( Department 
Medicinal botany,  NIS and SCRI  and purified. The medicine was prepared in 
Gunapadam laboratory of National institute of Siddha. 
 
PREPARATION OF TRIAL DRUGS:
[8] 
A. Internal Medicine: POORA PARPAM: Ref: Veerama munivar vagada 
thiratu,part-2,S.P.Ramachandran,Edition-sep 1994 :pg.no-69&70].
 
 
Ingredients: 
1. Purified pooram (calomal)  - 3 1/4 varagan(13.65 gms) 
2. Latex juice of Calotropis gigentia, linn  - 14 palam (490 grms) 
3. Juice of Allium cepa, linn  - 14 palam (490 grms) 
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STANDARD OPERATING PROCEDURE:  
METHOD OF PURIFICATION OF RAW DRUGS
[6]
:  
Kammaru vetrilai-1/4 palam (8.75 Gms) 
Milagu –1/4 palam (8.75 Gms) 
The above mentioned 2 Ingredients were made into paste by water. In a mud pot 
1.3lit  water(1.padi) was taken, and the paste was mixed with water.The raw drug  
pooram was tied  in a dry clean cloth ,and immersed  into the water and constantly 
heated until  the water reduced into ¾ part.then The pooram was taken out washed 
with pure water.  
 
ALLIUM CEPA: Pealed off the outer skin. 
 
METHOD OF PREPARTION: 
Purified Pooram wasplaced in a clean dry cloth,.The above mentioned quantity 
of latex  of Calotropis gigentia was taken in a mud pot and pooram covered with the 
cloth was immersed into the erukan pal and constantly heated until the  latex dried 
out.Then it was ground into paste with small onion juice and was made into small 
pills and dried in shade.pills were placed in a mud plate and covered with similar size 
of mud plate.The margines of the plates were covered with clay pasted cloth.The 
plates were placed inside the pit and pudam  carried out with 40 palam cow dung 
cakes(1400 gms).Next morning the mud plates were removed and finished poora 
parpam was collected.  
 
Drug storage:     
 
The prepared drug was stored in a clean and dry wide mouthed glass 
container. 
 
Dispensing: 
The prepared drug was dispensed in sachets (6mg each) Patients will be 
advised to collect the medicines once in 4days for 8days. At each visit the patients 
were advised to return the unconsumed drug if   any. 
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Drug administration: 
The prepared drug was given for 4 days followed by 4 days of break, again the 
medicine was given foe 4 days. 
 
EXTERNAL MEDICINE: 
STANDARD OPERATING PROCEDURE FOR “NATHAICHOORI 
ENNAI” [9]: Ref: Sarabenthira vaithiya muraigal (Vadharoga sigichai), edition 
IV,nov-1998,pg:1. 
 
Required raw drugs:  
1. Mutrina nathaichoori ver (Spermacoce hispida, linn)-3 palam (105gms) 
2. Vasambu (Acorus calamus, linn)                  - 3/4 palam (26.25gms) 
3. Poondu (Allium sativum, linn)                     - 1/4 palam (8.75gms) 
4. Amanaku ennai (Ricinus communi, linn)     - 1 padi (1.3 lit) 
 
PURIFICATION OF TRIAL DRUGS: 
ROOT OF NATHAI CHOORI:  Washed with water 
VASAMBU    :  Burnt the acorus calamus until it turned into charcoal. 
POONDU     :  Pealed off the outer skin 
 
METHOD OF PREPARATION: 
Above mentioned 3 drugs were made into paste and mixed with castor oil the 
mixture was allowed to boil till it reduced the thylam consistency and finally the oil 
was filtered, and collected in a glass container.  
 
DRUG STORAGE: 
The prepared oil was stored in a clean and dry wide mouthed glass bottle. 
DISPENSING: The prepared oil was dispensed in bottle (80 ml) once in 4days for 
8days. 
 
 
 
 
 
  
Review of Drug 
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1.âÃõ 
MERCUROUS CHLORIDE (CALOMEL) 
[7]
 
         
  þ¨¼Å¡¾ Ý¨Ä ¦ÂÃ¢Ý¨Ä ÌýÁó  
 ¦¾¡¨¼Å¡¨Æ Å¡¾Á¡ï §º¡½¢-Â¢¨¼Â¡§¾¡ 
 ¦Å¡ìÌÃº ¸÷ôâÃ ¦Á¡ý§È¡ ÂÇÅ¢Î¿ø  
 þìÌ¦ÅøÄò §¾è¿¡Ç£. 
      
¦À¡Õû : 
 ¾£.À¢:þÎô¨À ÀüÈ¢Â Ý¨Ä, Å¡¾ÌýÁõ, ¦¾¡¨¼ Å¡¨Æ, Å¡¾Ãò¾, 
§¿¡ö,ÍÃõ, Áïºð¸¡Á¡¨Ä, À¢ò¾ §¾¡¼õ, º£¾§À¾¢, ¿£÷§¸¡¨Å, Å¢Ã½ ºó¿¢, 
È¡¾ Å¢Ã¨½í¸û, §Á¸ Å¢Â¡¾¢, ¦ºÃ¢Â¡¨Á, Å¡ó¾¢, §À¾¢, ¸¢ÕÁ¢ ¦¿¡ö, 
¸£øÅ¡¾õ, ¦º¡È¢, º¢ÃíÌ, ÁÄÀó¾õ Ó¾Ä¢ÂÉ ¾£Õõ. 
 
Throbbing pain in the lumbar region,burning sensation,ulcer due todisorders 
of vadham humour,hepatomegaly,pyrexia,jaundice,basiilary dysentery,dropsy,chronic 
ulcer,venereal diseases,indigestion,vomiting,diarrhoea,worm infestation, rheumatism, 
itching, constipation, and scabies
[20].
 
 
Í¨Å  : ¯ôÒ,¸¡÷ôÒ  
Å£¡¢Âõ : ¦ÅôÀõ 
À¢¡¢×  : ¸¡÷ôÒ 
 
¦ºö¨¸ 
¯¼ø§¾üÈ¢-Alterative   
¯Á¢ú ¿£÷ ¦ÀÕì¸¢-Sialagogue 
¸¢ÕÁ¢ ¿¡º¢É¢-Anti septic 
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2.±ÕìÌ – Calortropis gigantean.lin [13] 
 English name :Mudar 
 Telungu : jilledu-chettu 
 Malayalam : Erukka      
 Kannadam : Yakkeda-gida 
 Sanskrit : arka     
 Hindi :Akan 
§ÅÚ ¦ÀÂ÷ : «Õì¸ý 
Í¨Å   :  ¨¸ôÒ ,¸¡÷ôÒ ,ÁÐÃõ 
¾ý¨Á  :  ¦ÅôÀõ  
À¢¡¢×   :  ¸¡÷ôÒ 
 
¦ºö¨¸ 
¦ÅôÀÓñ¼¡ì¸¢ - Stimulant 
¯¼ø§¾üÈ¢-Alterative   
ÁÄÁ¢Äì¸¢-Laxative 
ÒØì¦¸¡øÄ¢-Anthelmentic 
 
Ì½õ  
Áý¨ÉÔí ¨¸¦ÂÎì¸ ¨Åò¦¾Â¢üÈ¢ §ÉÂ¸üÈ¢ 
ÔýÛ À¢½¢¨Â §Â¡ðÎ¾Ä¡ü-¦º¡ý§Éý  
±Õì¦¸É§Å âÁ¢ Â¢É¢§Ä Å¢ÇíÌ 
"Õì¸ ÁÕì¸¦ÉÉ Ä¡õ.(§¾.¦ÅñÀ¡) 
  
¦À¡Õû :±ÕìÌ ,ÅÇ¢(Å¡¾)§¿¡ö¸ÙìÌ ¿ýÁÕó¾Ìõ;ÀÄ §¿¡ö¸¨Ç 
§À¡ìÌõ. ³Â §¿¡ö¸Ç¡¸¢Â þÕÁø,þ¨ÃôÒ þ¨Å¸¨ÇÔõ µðÊÅ¢Îõ 
 
 It is good for deranged vadha humour,it also cures cough and bronchial asthma. 
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CHEMICAL COMPONENTS
 [19]
 
 Calotrropin  
 Calotoxin 
 Uscharincalotanic acid 
 19-nor ad 18, 20-epoxy-cardinolides 
 Calotroposides A and B 
 Oxypregnanneoligo glycosides 
 Giganticine 
 
3.¦Åí¸¡Âõ- Allium cepa.lin [13] 
§ÅÚ ¦ÀÂ÷:®ÕûÇ¢ ,¯ûÇ¢ ,®Ã×ûÇ¢ ,®Ã¦Åí¸¡Â¡õ, ¸¡Âõ, Íì¸¢Ãó¾õ 
¿¢îºÂõ, ÀÄ¡ñÎ  
 
ÀÂýÀÎõ ¯ÚôÒ  : â, ¸¢ÆíÌ, Å¢¨¾ (Flower,Tuber,Root) 
Í¨Å    : ¨¸ôÒ ,¸¡÷ôÒ 
¾ý¨Á  : ¦ÅôÀõ 
À¢¡¢×    : ¸¡÷ôÒ 
 
¦ºö¨¸ 
¦ÅôÀÓñ¼¡ì¸¢-stimulant 
º¢Ú¿£÷¦ÀÕì¸¢-Diuretic 
§¸¡¨ÆÂ¸üÈ¢-Expectorent 
Ý¾¸Óñ¼¡ì¸¢ -Emmenagogue 
¾ÊôÒñ¼¡ì¸¢-Rubefacient 
¯ûÇÆÄ¡üÈ¢-Demulcent 
¸¡Áõ¦ÀÕì¸¢-Aphrodisiac 
ÀñÒ 
¦ÅôÀã Äí¸¢Ãó¾¢ Å£ÚÃò¾ À¢ò¾Ó¼ý 
¦ºôÒ¿¡ «ì¸¢Ãó¾£ Ã¡ò¾¡¸õ-¦ÅôÒì 
¸ÎôÀÚÁó ¾ïºó¿¢ ¸¡ºõÅÂ¢ü ÚôÀø 
¾Êô§ÀÚõ ¦Åí¸¡Âò¾¡ø 
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¦À¡Õû : ¯¼Ä¢ý ¦ÅôÀõ, ãÄõ, º¢ÃíÌ, ÌÕ¾¢ÂÆø, «ì¸Ãõ, 
¿£÷§Åð¨¸, ¸Æ¢îºø Ó¾Ä¢ÂÉ ¾£Õõ. 
        Body heat, hemorrhoids, scabies, hypertension, aphthous ulcer, diarrhoea, 
excessive thirst. 
 
CHEMICAL COMPONENTS
 [22][19] 
Organic sulfur 
 thiosulfinates 
 Cepaenes 
  S-oxides 
Quercetin 
Alyl sulfides 
Flavonoids 
                  
4. ¿ò¨¾ÝÃ¢ – Spermacoce hispida.lin [13] 
 English name: Shaggy buttonweed 
 Telungu: Madana-chettu 
 Malayalam: Thartavel   
 Sanskrit: Shri-gandha chandanam  
 Hindi: Madana ganti 
 
§ÅÚ ¦ÀÂ÷   :¸Î¸õ, ÌÆ¢Á¢ð¼¡ý, ÝÃ¢, ¾¡Õ½¢,  ¦¾¡Ä¢Â¡¸Ãõ¨À 
ÀÂýÀÎõ ¯ÚôÒ  : Å¢¨¾,§Å÷(Seed,Root) 
Í¨Å   : þÉ¢ôÒ  ÐÅ÷ôÒ,. ¾ý¨Á: ¾ðÀõ À¢¡¢× : þÉ¢ôÒ 
¦ºö¨¸ : 
§Å÷(Root) 
 ¯¼ü§ÈüÈ¢ - Alterative 
 ÌÇ¢÷îº¢Ôñ¼¡ì¸¢ - Cooling 
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ACTION :
[31,32] 
 Analgesic 
 Anti-oxidant 
 Anti inflamatory 
        
5.¬Á½ìÌ- Ricinus communis.lin [13] 
 Telungu: Madana-chettu 
 Malayalam: Thartavel   
 Sanskrit: Shri-gandha chandanam  
 Hindi: Madana ganti 
 
§ÅÚ ¦ÀÂ÷:²Ãñ¼õ, º¢ò¾¢Ãõ ,¾ÄåÀõ 
Í¨Å   :  ¨¸ôÒ  
¾ý¨Á :  ¦ÅôÀõ 
À¢¡¢×   :  ¸¡÷ôÒ 
¦ºö¨¸  : 
À¡ü¦ÀÕì¸¢ - Galactagogue 
Å¡¾Á¼ì¸¢ - Anti vadha  
ÀÂýÀÎõ ¯ÚôÒ : Å¢¨¾ ,§Å÷(Seed,Root) 
 
ÀñÒ 
Å¡¾ò ¦¾¡¼ì¨¸ ÅÃ¦Å¡ð¼¡ ÁüÀÊìÌ 
¸¡¾òÐì ¸ôÀ¡ü-Ý¾ò¨¾ô 
§ÀÃñ¼ Àó¾¢ìÌõ §À¾¢ìÌõ §¿¡ö¸¡ð¨¼ 
§ÂÃñ¼õ ¦ÁýÀ¾¢ý§Â. (§¾.¦ÅñÀ¡) 
¦À¡Õû : º¢üÈ¡Á½ìÌ ¸Æ¢îº¨Ä ¯ñ¼¡ìÌõ, ÅÇ¢ ÌüÈò¨¾ 
±Æ¦Å¡ð¼¡Áø ¾ÎìÌõ. 
 It inducec loose stools, and dominates vadha humour. 
  
53 
 
CHEMICAL COMPONENTS
 [19]
 
 Ricinoleste of glycerol 
 Tri-ricinolein 
 Palmitin 
 Stearin 
 Viscid oil 
 Glyceride of dihydroxy stearic acid 
6.ÅºõÒ-ACORUS CALAMUS [13] 
 English: Sweef-flag 
 Telungu: vasa 
 Malayalam: vayambu  
 Sanskrit: vacha  
 Hindi: Bach 
§ÅÚ ¦ÀÂ÷   :  ¯ì¸¢Ãõ, Åºõ, Å¨º, §Å½¢, ÍÎÅ¡ý, ¯¨ÃôÀ¡ý,  
§À÷ ¦º¡øÄ¡ ÁÕóÐ, À¢û¨Ç ÁÕóÐ. 
ÀÂýÀÎõ ¯ÚôÒ  :  §Å÷ (Root) 
Í¨Å    : ¸¡÷ôÒ 
¾ý¨Á   : ¦ÅôÀõ 
À¢¡¢×    : ¸¡÷ôÒ 
 
ÀñÒ: 
À¡õÀ¡¾¢ ¿ïºü Ò¾ôÒñ ÅÄ¢ Å¢¼À¡¸í ÌýÁõ 
ÝõÀ¡Ã¢Ãò¾ À¢ò¾Ó¸ ¿¡üÈõÅý Ý¨ÄºýÉ¢ 
Å£õÀ¡õ¨À ¸¡ºõ À¢Ä¸ï º¢Ä¢ À¾õ Å£È¢ÕÁø 
¾¡õÀ¡í ¸¢ÕÁ¢ Â¢¨Å §ÂÌ Á¡º¢Å ºõÀ¢¨É§Â 
 
¦À¡Õû : 
±øÄ¡ ¿ïÍ¸û, Òñ Å¨¸¸û, ³Å¨¸ ÅÄ¢,ÌýÁõ, Ãò¾À¢ò¾õ, 
Å¡ö¿¡üÈõ, Ý¨Ä, ÓôÀ¢½¢, þÕÁø, ®Ãø§¿¡ö, Â¡¨Éì¸¡ø, ¿¡¼ôÒØ 
Ó¾Ä¢ÂÉ ¾£Õõ.  
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Toxins, five types of epilepsy, gastritis, hypertension, halitosis, delirium, pricking 
pain, liver diseases, filariasis. 
 
CHEMICAL COMPONENTS
 [19] 
 Acorin 
 Acoretin 
 Calamine 
 As aryl-aldehyde 
 Heptylic and palmitic acid 
 Eugenol 
 Pinene 
 Camphene   
 
7.¦ÅûÙûÇ¢-Allium sativum.lin [13] 
 English: Garlic 
 Telungu: Thella-gada 
 Malayalam: Velluli  
 Sanskrit: Lasuna  
 Hindi: Lashan 
 
§ÅÚ ¦ÀÂ÷ :  
þÄÍÉõ,¸¡Âõ,¯ûÇ¢,âñÎ,¦Åû¨ÇâñÎ,¦Åû¦Åí¸¡Âõ. 
 
ÀÂýÀÎõ ¯ÚôÒ :¸¢ÆíÌ(Tuber) 
 
¦ºö¨¸ : 
«¸ðÎÅ¡öÅ¸üÈ¢-Carminative 
Àº¢ ¾£àñÊ-Stomachic 
 ¯ÃÁ¡ì¸¢ -Tonic 
¯¼ü§¾üÈ¢-Alterative 
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¦ÅôÀÓñ¼¡ì¸¢ -Stimulant 
§¸¡¨ÆÂ¸üÈ¢ -Expectorent 
º¢Ú¿£÷¦ÀÕì¸¢ -Diuretic 
ÒØì¦¸¡øÄ¢-Anthelmintic 
 
ÀñÒ 
ºýÉ¢§Â¡Î Å¡¾ó¾¨Ä §¿¡× ¾¡ûÅÄ¢ 
ÁýÉ¢ÅÕ ¿£÷§¸¡¨Å Åýº£¾õ-«ýÉ§Á 
¯ûÙûÇ¢ ¸ñÀ¡ö ¯¨ÇãÄ §Ã¡¸Óõ §À¡õ 
¦ÅûÙûÇ¢ ¾ýÉ¡ø ¦ÅÕñÎ 
 
¦À¡Õû : ¦ºÅ¢Î, ¿¡ðÀð¼ þÕÁø, þ¨ÃôÒ, ÅÂ¢üÚôÒØ, ÓôÀ¢½¢ 
ÅÇ¢§¿¡ö¸û, ³Â¾¨ÄÅÄ¢, Å¡ö§¿¡ö, ¿£§ÃüÈõ, Ó¾Ä¢ÂÉ ¾£Õõ 
 
Deafness, chronic cough, bronchial asthma, worm infestation, delirium, 
hemorrhoids, headache due to deranged kabam, mouth disorders. 
 
CHEMICAL COMPONENTS
 [19] 
 Acrid volatile acid 
 Starch 
 Mucilage 
 Albumin 
 Allyl propyl disulphide 
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1. GENDER  
 
1. Gender distribution 
 
GENDER NUMBER OF CASES PERCENTAGE% 
Male 12 30 
Female 28 70 
total 40 100 
 
 
Inference:  
 
Among 40 cases, the disease was found to be higher in Female i.e. (70%). 
 
 
 
 
 
 
 
 
 
 
\ 
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2. AGE 
 
2. Age Distribution 
 
AGE(YEAR) NUMBER OF CASES PERCENTAGE% 
41-50 16 40 
51-60 24 60 
total 40 100 
 
 
Inference: 
 
Among 40 cases, the disease was found to be higher in the age group 51-60 years. 
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3. Kalam distribution 
 
Vaatha  kaalam   - 1 case (2.5 %) 
Pitha  kaalam  - 39 cases (97.5) 
Kaba kaalam  - 0 case 
 
 
Inference: 
 
Out of 40 cases, 39 cases were found to be in Pitha kaalam, i.e. between 33 – 
66 years and 1 case was found to be in Vaatha kaalam (31-32 years). 
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4. Occupational status 
 
OCCUPATION NUMBER OF CASES PERCENTAGE% 
Coolie 8 20 
Sales man 7 17.5 
Farmer  2 5 
Teacher 5 12.5 
House maker 18 45 
Total 40 100 
 
 
 Inference: 
 
Out of 40 cases, 26 patients (45 %) were Home makers. 
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5. Seasonal variation : 
 
SEASON NUMBER OF CASES PERCENTAGE% 
Kaar kaalam - - 
Koothir kaalam - - 
Munpani  kaalam 25 62.5 
Pinpani  kaalam 15 37.5 
Elavenil kaalam - - 
Muthuvenil kaalam - - 
Total 40 100 
 
 
Inference: 
 
Out of 40 cases, 25 patients (62.5%) were admitted in Munpani Kaalam and 
15patients (37.5%) were admitted in Pinpani Kaalam. 
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6. Thinai 
 
THINAI NUMBER OF CASES PERCENTAGE% 
Kurinji - - 
Mullai 5 12.5 
Marurham 5 12.5 
Neithal 30 75 
Paalai - - 
total 40 100 
 
 
Inference: 
 
 Among the 40 patients, 5 patients (12.5 %) were from Mullai and 5 patients 
(12.5 %) were from Marutham and 30 patients (75 %) from Neithal Thinai. 
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7. SOCIO- ECONOMIC STATUS 
 
SOCIO- ECONOMIC 
STATUS 
NUMBER OF 
CASES 
PERCENTAGE% 
HIGHER INCOME 8 20 
MIDDLE INCOME 12 30 
LOWER INCOME 20 50 
Total 40 100 
 
 
Inference: 
 
Out of 40 cases 20% cases from upper and 30% cases were from middle class and 
50% from lower class. 
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8. DIETARY HABITS: 
 
DIETARY HABITS NUMBER OF 
CASES 
PERCENTAGE% 
VEGETARIAN 10 25 
NON- VEGETARIAN 30 75 
TOTAL 40 100 
 
 
Inference: 
 
Out of 40 cases 75% of cases were Non-vegetarians and 25% of cases were 
Vegetarians 
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9. PRECIPITATING FACTOR 
 
PRECIPITATING FACTOR 
 
NUMBER OF 
CASES 
PERCENTAGE% 
OBESITY 14 35 
OBESITY WITH 
MENOPAUSE 
12 30 
OCCUPATION RELATED 14 35 
H/O TRAUMA 0 0 
TOTAL 40 100 
 
 
 
Inference: 
 
Out of 40 cases 35% of cases were Obesity.  
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10. DISTRIBUTION OF MUKKUTRAM: 
 
a. VAATHAM: 
Out of 40 cases Viyanan and Samanan were affected in all the 40 patients 
(100%). 
 
b. PITHAM: 
Out of 40 cases saathagam was affected in almost all the 40 cases (100%) 
 
c. KABAM: 
Out of 40 cases Santhigam was affected in almost all the 40 cases (100%). 
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11. UDAL THATHUKKAL: 
 
The Seven thathukkal which constitute our body structure and help to maintain 
the normal physiological functions get changed in Pathological conditions. 
Among the 7 Udal Kattugal, Saaram , kozhuppu and Enbu were affected in all 
the 40 cases (100%). 
 
 
UDAL THATHUKKAL NUMBER OF CASES PERCENTAGE% 
SARAM  40 100 
SENNEER 0 0 
OON 0 0 
KOZHUPPU 40 100 
ENBU 40 100 
MOOLAI 0 0 
SUKKILAM/SURONITHAM 0 0 
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12. ENVAGAI THERVUGAL: 
In Siddha system of Medicine, the eight types of investigative procedure were 
adopted for clinical approach and diagnosis. The investigations were done properly 
and observations were tabulated. 
 
 
13. NEERKURI 
 
NIRAM NUMBER OF CASES PERCENTAGE% 
YELLOW 16 40 
PALE YELLOW 24 60 
DARK YELLOW - - 
 
 
Inference: 
 
Out of 40 cases, in 60% of cases urine was pale yellow in colour. 
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14. NEIKKURI: 
 
 
NEIKKURI NUMBER OF CASES PERCENTAGE% 
VAATHAM 32 80 
PITHAM 7 17.5 
KABAM 1 2.5 
TOTAL 40 100 
 
 
Inference: 
 
Out of 40 cases, in 80% of cases Neikkuri was found as Vaatham. 
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15. NAADI: 
 
NAADI NUMBER OF CASES PERCENTAGE% 
VAATHA PITHAM 30 75 
VAATHA KABAM 1 2.5 
PITHA VAATHAM 8 20 
PITHA KABAM - - 
KABA VAATHAM 1 2.5 
KABA PITHAM - - 
TOTAL 40 100 
 
 
Inference: 
 
Among 40 cases, vaathapitham naadi was found in 30patients, 8 were found in 
Pithavaatham and Vaathakabam, Kabavaatham for each 1 cases. 
 
 
 
 
 
 
 
 
71 
 
16. DISTURBANCES IN KANMENTHIRIYAM: 
 
 
KANMENDRIYAM NUMBER OF CASES PERCENTAGE% 
Kai 0 0 
Kaal 40 100 
Vai 0 0 
Eruvai 0 0 
Karuvai 0 0 
total 40 100 
 
Inference:  
Kaal was affected in all the 40 cases (100 %) 
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17.DURATION OF ILLNESS 
 
 
DURATION OF 
ILLNESS 
NUMBER OF CASES PERCENTAGE% 
6 MONTHS- 1 YEAR 17 42.5 
1-2 YEARS 15 37.5 
2-3 YEARS 7 17.5 
ABOVE 5 YEARS 1 2.5 
total 40 100 
 
Inference:  
Among the 40  patients 17 patients were under 6 months to 1 year duration. 
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18. INVOLVEMENT OF KNEE JOINTS: 
 
INVOLVEMENT OF KNEE 
JOINTS 
NUMBER OF 
CASES 
PERCENTAGE% 
BOTH KNEE JOINTS 32 80 
SINGLE KNEE JOINT ONLY 8 20 
TOTAL 40 100 
 
 
Inference: 
 
Out of 40 cases both knee joints were affected in 32patients (80%). 
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1. UNIVERSAL PAIN ASSESMENT SCALE: 
 
 
 
A. 0: No Pain 
B. 1 -3: Mild pain 
C. 4-6: Moderate pain 
D.7-9: Severe pain 
E.10: Worst possible pain 
 
2. RESTRICTED MOVEMENT ASSESSMENT SCALE:     
            
Gradation of movements: 
 Grade 1 - Fit for all activities, do their work without support. 
 Grade II - Mild pain present in knee joint, mild restricted movements. 
 Grade III - Pain present in knee joint, moderate restriction of movements. 
 Grade IV - Severe pain, bed ridden. 
(Ref: Clinical manual for nursing practice (National Institute of Health Warren 
Grant Magnuson Clinical Centre) 
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19. CLINICAL FEATURES.BT/AT 
 
CLINICAL 
FEATURES 
BT AT BT(%) SYMPTO
MS 
REDUCED 
AT(%) 
PAIN 40 10 100 30 75 
SWELLING 29 8 72.5 21 20 
WARMTH 13 5 32.5 8 12.5 
MORNING 
STIFFNESS 
14 3 35 11 7.5 
TENDERNESS 22 4 55 18 10 
CREPITATION 40 30 100 10 75 
DEFORMITY - - - - - 
RESTRICTED 
MOVEMENTS 
40 10 100 30 25 
 
Inference:Out of 40 cases, Restriction of movement reduced for 30 cases. 
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20. RESULTS – AFTER TREATMENT-PAIN SCORE 
 
RESULT NUMBER OF 
CASES 
PERCENTAGE% 
GOOD IMPROVEMENT 30 75 
MODERATE IMPROVEMENT 6 15 
MILD IMPROVEMENT 4 10 
TOTAL 40 100 
 
 
Inference: 
 
Out of 40 cases, good improvement was observed in 30 patients, moderate 
improvement in 6 patients, and mild improvement in 4 patients. 
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21. SECONDARY OUTCOME-. RESTRICTED MOVEMENT ASSESSMENT 
SCALE 
 
 
RESULT NUMBER OF 
CASES 
PERCENTAGE% 
BT AT BT AT 
GRADE1 0 0 0 0 
GRADE 2 24 20 60 50 
                  GRADE3 16 10 40 25 
GRADE 4 0 0 0 0 
TOTAL 40 30 100 75 
 
 
 
 
 
Inference: 
 
Out of 40 cases, restriction of movement reduced for 30 cases (75%). 
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IPD CASES CLINICAL IMPROVEMENT 
 
 
 
OPD CASES CLINICAL IMPROVEMENT 
 
Sl.NO IP NO AGE SEX DOA DOD PAIN 
SCORE   
IMPROVEMENT 
BT AT 
1 7513 50 F 11.12.15 27.12.15 3 0 GOOD 
2 7516 49 F 13.12.15 29.12.15 6 1 MODERATE 
3 7537 52 F 20.12.15 5.1.16 7 0 GOOD 
4 7603 53 F 21.12.15 6.1.16 5 0 GOOD 
5 7621 55 F 28.12.15 13.1.16 2 0 GOOD 
6 7625 45 F 8.1.16 24.1.16 9 4 MILD 
7 7671 50 F 9.1.16 25.1.16 8 0 GOOD 
8 7817 50 F 13.1.16 29.1.16 5 0 GOOD 
9 7932 49 F 13.1.16 29.1.16 6 1 MODERATE 
10 7941 56 F 25.1.16 11.1.16 7 0 GOOD 
 
Sl. 
 
OP NO 
 
AGE 
 
SEX 
 
PAIN SCORE   
IMPROVEMENT 
BT 
 
B AT 
11 H15914 59 M 6 0 GOOD 
12 H16062 45 F 5 0 GOOD 
13 H16214 59 M 1 0 GOOD 
14 H16712 52 F 7 0 GOOD 
15 H16756 47 F 4 0 GOOD 
16 H16912 56 M 2 2 MODERATE 
17 H17115 49 M 6 0 GOOD 
18 H19071 53 F 8 0 GOOD 
19 H19442 48 M 4 0 GOOD 
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20 H19489 52 F 3 0 GOOD 
21 H21084 45 M 9 5 MILD 
22 H21399 58 F 6 0 GOOD 
23 H21836 59 F 1 0 GOOD 
24 H22560 58 M 6 0 GOOD 
25 H23059 49 F 7 2 MODERATE 
26 H23060 60 M 5 0 GOOD 
27 H29115 57 F 3 0 GOOD 
28 H29292 55 F 4 0 GOOD 
29 H29300 55 M 7 0 GOOD 
30 H29571 60 M 6 6 MILD 
31 H29914 48 F 2 0 GOOD 
32 H35873 50 F 5 0 GOOD 
33 H37384 55 M 8 6 MILD 
34 H41531 55 F 5 0 GOOD 
35 H42222 41 M 5 1 MODERATE 
36 H45398 50 F 6 0 GOOD 
37 H46888 55 F 5 0 GOOD 
38 H47892 57 F 9 0 GOOD 
39 H51842 54 F 2 0 GOOD 
40 H52221 58 F 7 2 MODERATE 
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INVESTIGATIONS BEFORE AND AFTER TREATMENT – IP AND OP 
PATIENTS 
 
SL.NO 
IP 
NO/OP 
NO 
AGE 
 
SEX 
 
Hb gm% TRBC Million/cumm 
Before 
Treatment 
After 
treatment 
Before 
treatment 
After 
Treatment 
1 7513 50 F 10 11.1 4.3 4.4 
2 7516 49 F 11.1 12.2 4.8 4.9 
3 7537 52 F 13 12.1 4 4.3 
4 7603 53 F 13.6 13.6 4.1 4.2 
5 7621 55 F 12.3 11.3 4.3 4.4 
6 7625 45 F 13 13.2 4.2 4 
7 7671 50 F 12.1 13.2 5.4 4.4 
8 7817 50 F 12.8 13.1 4.7 4.9 
9 7932 49 F 12.4 13.3 5.1 5.2 
10 7941 56 F 13.1 13.2 5.0 4.5 
11 H15914 59 M 16 15.3 4.7 4.9 
12 H16062 45 F 11.3 14.2 4.4 4.6 
13 H16214 59 M 14.3 14.1 4.3 4.7 
14 H16712 52 F 13.6 13.7 4.5 4.3 
15 H16756 47 F 11.2 13.5 5.1 5 
16 H16912 56 M 15.2 16.1 4.3 4.4 
17 H17115 49 M 16.1 16.2 4.7 4.5 
18 H19071 53 F 11.2 11.5 4.9 4.8 
19 H19442 48 M 14.6 15.2 4.6 4.8 
20 H19489 52 F 12.1 13.7 5.06 4.9 
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HB AND RBC – INVESTIGATIONS BEFORE AND AFTER TREATMENT – 
IN OPD 
 
S.NO OPNO AGE SEX 
Hb gm% TRBC Million/cumm 
Before 
Treatment 
After 
treatment 
Before 
treatment 
After 
Treatment 
21 H21084 45 M 13.2 13.5 4.9 4.5 
22 H21399 58 F 13 13.4 4.5 4.7 
23 H21836 59 M 13.1 13.4 4.6 4.4 
24 H22560 58 F 11.7 12.3 4.2 4.2 
25 H23059 49 F 12.3 13.4 4.7 4.9 
26 H23060 60 M 12.7 13.3 4.2 4.4 
27 H29115 57 M 15.5 15.8 6.6 6.8 
28 H29292 55 F 10.3 11.1 4.7 4.6 
29 H29300 55 M 14.6 15.3 5.1 5 
30 H29571 60 F 13.3 13.6 4.9 4.6 
31 H29914 48 F 9.4 10.5 4 4.3 
32 H35873 50 F 10.4 11.2 5.4 4.9 
33 H37384 55 M 11 11.1 4.6 4.6 
34 H41531 55 F 13.3 13.5 4.2 4.1 
35 H42222 41 M 11.5 11.6 4.1 4.2 
36 H45398 50 F 12.5 13.5 4.4 3.8 
37 H46888 55 F 10.7 11 4.8 4.8 
38 H47892 57 F 12.8 12.7 4.6 4.4 
39 H51842 54 F 12.9 13 4.8 4.8 
40 H52221 58 F 13.4 13.2 4.6 4.5 
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CHOLESTEROL PROFILE OF THE   IP AND OP PATIENTS (BEFORE AND 
AFTER TREATMENT) 
 
S.NO 
IP NO 
/OPNO 
T.CHOLESTEROL 
(mg/dl) 
HDL 
(mg/dl) 
LDL 
(mg/dl) 
VLDL 
(mg/dl) 
TGL 
(mg/dl) 
BT AT BT AT BT AT BT AT BT AT 
1 7513 200 198 38 51 110 66 26 34 178 160 
2 7516 172 171 45 59 94 98 26 23 79 79 
3 7537 189 196 38 45 92 94 17 16 134 80 
4 7603 183 182 38 41 92 96 22 34 104 98 
5 7621 191 170 39 40 93 88 10 18 106 143 
6 7625 170 177 38 40 91 88 26 26 116 118 
7 7671 198 182 38 37 86 93 34 17 116 127 
8 7817 199 193 38 36 116 107 11 22 73 117 
9 7932 165 193 46 42 91 87 54 10 101 109 
10 7941 190 186 140 47 88 83 29 26 150 135 
11 H15914 176 152 37 33 116 105 29 34 85 156 
12 H16062 187 168 27 41 108 96 35 11 75 98 
13 H16214 148 146 32 36 128 108 22 26 136 132 
14 H16712 195 183 35 46 77 73 17 23 112 58 
15 H16756 181 169 134 78 128 94 26 21 110 126 
16 H16912 133 123 35 33 117 123 22 35 135 145 
17 H17115 199 176 49 46 69 87 18 27 96 137 
18 H19071 249 197 44 42 53 56 24 38 83 142 
19 H19442 199 180 47 47 135 124 19 19 73 118 
20 H19489 187 172 47 42 51 62 19 24 110 152 
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CHOLESTEROL PROFILE OF THE   OPD PATIENTS (BEFORE AND 
AFTER TREATMENT) 
 
S.NO OP NO 
T.CHOLESTEROL 
(mg/dl) 
HDL 
(mg/dl) 
LDL 
(mg/dl) 
VLDL 
(mg/dl) 
TGL 
(mg/dl) 
BT AT BT AT BT AT BT AT BT AT 
21 H21084 178 154 47 37 67 86 21 18 103 73 
22 H21399 175 166 53 33 106 102 16 18 79 152 
23 H21836 207 196 35 37 93 77 13 19 66 138 
24 H22560 233 196 46 33 99 110 23 25 115 149 
25 H23059 135 120 48 34 92 91 31 33 154 51 
26 H23060 180 156 38 39 88 82 25 22 123 63 
27 H29115 155 152 40 41 109 110 13 12 66 110 
28 H29292 170 186 50 34 101 98 30 29 152 78 
29 H29300 197 172 46 45 87 89 28 32 106 71 
30 H29571 141 180 35 41 114 110 30 26 116 110 
31 H29914 183 171 30 38 93 92 10 12 143 143 
32 H35873 147 134 36 34 88 87 12 15 110 118 
33 H37384 210 198 42 53 76 78 15 17 69 68 
34 H41531 223 220 38 45 120 118 31 30 132 149 
35 H42222 160 172 46 67 87 58 24 18 142 136 
36 H45398 200 196 40 46 112 67 21 18 119 130 
37 H46888 182 190 36 56 68 115 25 19 112 56 
38 H47892 140 142 38 48 75 130 16 25 87 65 
39 H51842 125 127 40 36 94 126 32 33 73 74 
40 H52221 206 200 33 48 123 69 36 22 159 156 
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BLOOD INVESTIGATIONS BEFORE AND AFTER TREATMENT- IP AND 
OP PATIENTS 
S. 
NO 
IP. NO/ 
OP. 
NO 
TC 
(million/ 
cu.mm) 
DC (%) ESR 
N L E Mxd ½ HR 1 HR 
BT AT BT AT B
T 
A
T 
B
T 
A
T 
BT AT BT A
T 
BT A
T 
1 7513 6100 7200 55 38 35 45 - - 10 17 16 4 32 10 
2 7516 6800 6700 70 56 26 34 - - 4 10 4 4 18 4 
3 7537 5300 6400 53 67 35 22 - - 12 11 2 2 16 6 
4 7603 6200 5400 41 55 53 36 - - 6 9 2 2 14 2 
5 7621 8600 9700 62 68 32 32 - - 6 10 24 24 52 32 
6 7625 5200 6600 60 52 30 34 - - 10 14 6 6 18 2 
7 7671 6300 7600 57 63 34 31 - - 9 6 12 2 42 8 
8 7817 4800 5600 70 62 27 32 - - 3 6 14 10 48 10 
9 7932 9200 8200 43 56 42 39 - - 5 8 22 8 14 4 
10 7941 5200 5400 58 72 37 21 - - 5 7 16 4 18 8 
11 H15914 6700 3100 69 71 25 25 - - 4 4 12 2 48 6 
12 H16062 8700 7600 60 66 36 29 - - 4 5 8 2 18 20 
13 H16214 5600 6500 54 68 37 21 - - 9 11 20 6 16 6 
14 H16712 5600 7200 48 49 37 36 - - 15 11 24 2 44 4 
15 H16756 6700 5800 65 63 30 30 - - 5 7 2 2 6 4 
16 H16912 5900 9700 54 57 38 38 - - 9 5 8 6 22 10 
17 H17115 5800 4100 57 68 30 28 - - 13 4 10 4 68 24 
18 H19071 7500 7800 51 52 37 37 - - 12 11 32 2 44 4 
19 H19442 5200 7200 55 64 40 32 - - 5 4 16 3 16 4 
20 H19489 7500 8800 62 57 30 29 - - 7 14 14 2 18 6 
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BLOOD INVESTIGATIONS BEFORE AND AFTER TREATMENT- OP 
PATIENTS 
 
S. 
NO 
OP. NO 
TC 
(million/ 
cu.mm) 
DC (%) ESR 
N L E Mxd ½ HR 1 HR 
BT AT BT 
A
T 
BT AT 
B
T 
A
T 
B
T 
A
T 
B
T 
A
T 
B
T 
A
T 
21 H21084 9100 8600 59 58 36 36 - - 4 6 2 2 4 2 
22 H21399 4500 6700 55 56 33 36 - - 8 6 6 4 4 2 
23 H21836 6800 7800 71 63 21 34 - - 3 4 4 2 6 4 
24 H22560 5400 4500 67 62 28 28 - - 10 8 2 2 10 4 
25 H23059 5600 6100 56 59 35 30 - - 11 3 2 4 22 8 
26 H23060 8500 5400 52 56 40 38 - - 6 6 4 6 26 6 
27 H29115 7800 7800 52 54 41 39 - - 7 7 4 8 18 6 
28 H29292 6700 9800 65 65 19 31 - - 4 6 8 6 12 4 
29 H29300 6300 11000 59 64 32 29 - - 7 8 
2
2 
10 8 4 
30 H29571 5400 8600 46 63 41 31 - - 13 6 
1
6 
8 10 6 
31 H29914 7100 7200 58 71 29 21 - - 3 8 2 2 34 8 
32 H35873 9300 5300 67 50 30 40 - - 3 10 
1
8 
10 20 10 
33 H37384 11000 4600 57 48 36 38 - - 7 14 4 4 14 10 
34 H41531 4600 7600 46 59 45 37 - - 9 4 8 4 4 2 
35 H42222 8400 8900 57 57 33 40 - - 10 3 4 2 2 2 
36 H45398 6400 9000 68 67 29 27 - - 3 6 4 2 18 6 
37 H46888 7200 9600 65 62 27 28 - - 8 10 
2
0 
10 22 8 
38 H47892 4300 5700 53 63 35 31 - - 12 6 2 4 42 8 
39 H51842 9200 6800 65 72 26 20 - - 9 8 6 4 24 6 
40 H52221 6300 7200 68 63 26 35 - - 6 2 4 2 8 2 
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SERUM BILIRUBIN & GLUCOSE PROFILE 
BEFORE AND AFTER TREATMENT – IP AND OP PATIENTS 
 
Sl. 
No 
IP 
N/OP 
.NO 
Serum bilirubin (mg/dl) 
GLUCOSE 
PROFILE 
Direct Indirect Total FAST P.P. 
BT AT BT AT BT AT BT AT BT AT 
1 7513 0.2 0.2 0.2 0.1 0.3 0.6 99 98 112 123 
2 7516 0.1 0.1 0.4 0.2 0.3 0.2 86 90 98 109 
3 7537 0.4 0.2 0.5 0.1 0.4 0.2 102 100 116 122 
4 7603 0.5 0.2 0.7 0.3 0.4 0.7 78 80 115 121 
5 7621 0.2 0.1 0.3 0.1 0.4 0.6 89 88 123 133 
6 7625 0.2 0.1 0.3 0.1 0.5 0.4 96 97 98 108 
7 7671 0.2 0.1 0.1 0.1 0.6 0.3 78 79 88 121 
8 7817 0.3 0.2 0.1 0.1 0.6 0.2 67 68 104 114 
9 7932 0.1 0.1 0.2 0.2 0.3 0.3 69 68 108 112 
10 7941 0.4 0.2 0.4 0.2 0.6 0 78 80 132 108 
11 H15914 0.1 0.2 0.6 0.3 0.5 0.5 97 96 128 110 
12 H16062 0.2 0.3 0.6 0.2 0.4 0.4 79 108 118 110 
13 H16214 0.2 0.2 0.1 0.2 0.4 0.4 103 65 120 108 
14 H16712 0.1 0.2 0.2 0.3 0.4 0.6 72 102 104 112 
15 H16756 0.1 0.1 0.5 0.4 0.5 0.5 105 101 106 122 
16 H16912 0.5 0.1 0.2 0.3 0.6 0.3 68 100 101 110 
17 H17115 0.4 0.3 0.3 0.3 0.2 0.4 90 99 108 0 
18 H19071 0.3 0.2 0.4 0.2 0.7 0.4 104 87 - 106 
19 H19442 0.2 0.1 0.5 0.4 0.6 0.4 88 76 104 112 
20 H19489 0.1 0.1 0.6 0.4 0.4 0.2 69 87 108 111 
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SERUM BILIRUBIN & GLUCOSE PROFILE 
BEFORE AND AFTER TREATMENT - OP PATIENTS 
 
Sl. 
No 
OP NO 
Serum bilirubin (mg/dl) 
GLUCOSE 
PROFILE 
Direct Indirect Total FAST P.P. 
BT AT BT AT BT AT BT AT BT AT 
21 H21084 0.5 0.2 0.2 0.3 0.6 0.4 92 96 103 99 
22 H21399 0.5 0.2 0.2 0.2 0.2 0.3 91 102 110 88 
23 H21836 0.5 0.3 0.3 0.2 0.3 0.2 106 102 118 102 
24 H22560 0.6 0.5 0.3 0.4 0.7 0.3 90 98 110 103 
25 H23059 0.4 0.5 0.2 0.2 0.4 0 91 85 110 101 
26 H23060 0.6 0.3 0.4 0.3 0.4 0.5 96 101 110 103 
27 H29115 0 0.2 0.4 0.3 0.5 0.4 93 96 118 82 
28 H29292 0.7 0.7 0.2 0.3 0.6 0.4 84 86 110 103 
29 H29300 0.8 0.6 0.2 0.3 0.6 0.9 91 96 118 105 
30 H29571 0.5 0.3 0.2 0.2 0.5 0.7 105 96 107 110 
31 H29914 0.8 0.6 0.2 0.3 0.3 0.2 89 84 112 109 
32 H35873 0.8 0.7 0.2 0 0.4 0.6 96 100 98 76 
33 H37384 0.7 0.9 0.2 0.1 0.4 0.5 91 98 116 98 
34 H41531 0.5 0.7 0.2 0.2 0.4 0.8 79 81 115 112 
35 H42222 0.8 0.7 0.2 0.2 0.5 0.7 91 105 123 147 
36 H45398 0.7 0.9 0.3 0.2 0.7 05 106 98 98 106 
37 H46888 0.7 1 0.2 0.2 0.6 0.2 88 89 88 120 
38 H47892 0.7 0.4 0.2 0.1 0.4 0.3 94 96 104 118 
39 H51842 0.8 0.6 0.2 0.1 0.4 0.7 89 97 108 130 
40 H52221 0.3 1 0.3 0.2 0.5 0.9 99 90 98 117 
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LIVER FUNCTION TESTS BEFORE AND AFTER TREATMENT - IP AND 
OP PATIENTS 
 
Sl. 
No 
IP 
NO/OP 
NO 
SGOT 
(IU/dl) 
SGPT 
(IU/dl) 
Al.pho 
(U/dl) 
Albumin 
(g/dl) 
Globulin 
(g/dl) 
T. 
Protein 
(g/dl) 
BT AT BT AT BT AT BT AT BT AT BT AT 
1 7513 18 17 14 15 75 73 4.5 4.3 2.2 2.1 6.7 6.3 
2 7516 21 20 19 20 94 92 4.7 4.1 2.7 2.5 7.4 7.3 
3 7537 26 27 29 28 102 83 4.3 4.2 2.9 2.8 7.1 7 
4 7603 25 80 30 23 75 69 4.0 3.5 2.5 3.0 6.5 6.5 
5 7621 15 16 10 10 93 91 5.2 4.9 2.4 2.7 7.9 7.5 
6 7625 16 18 9 12 82 89 4.7 4.6 2.8 2.7 7.5 7.6 
7 7671 18 19 12 17 95 103 4.8 4.3 2.5 2.4 7.2 6.7 
8 7817 13 18 17 15 96 94 3.5 3.6 2.7 2.6 6.2 6.2 
9 7932 19 0 21 0 107 105 4.0 0 2.3 0 6.3 0 
10 7941 19 18 20 19 101 87 4.2 3.5 3.1 3.0 7.3 6.5 
11 H15914 15 18 8 16 82 91 4.1 4.0 2.5 2.4 6.6 6.4 
12 H16062 15 18 8 16 83 92 4.1 4.0 2.5 2.4 6.6 6.4 
13 H16214 22 24 28 26 111 98 4.1 4.0 2.1 2.1 6.2 6.1 
14 H16712 23 24 26 25 117 110 3.9 3.8 2.4 2.4 6.3 6.2 
15 H16756 36 33 37 31 94 88 4.2 3.5 2.2 2 7.4 6 
16 H16912 19 20 27 25 109 113 3.3 3.1 3.0 3.0 6.3 6.1 
17 H17115 17 22 14 18 77 85 5.0 4.0 2.1 2.3 7.1 6.8 
18 H19071 19 20 15 18 82 86 4.6 4.2 2.2 2.4 6.8 6.6 
19 H19442 18 19 16 14 86 98 4.3 2.3 3 3.1 5.4 7.1 
20 H19489 18 17 15 16 99 110 4.1 4 3.1 3.1 7.2 7.1 
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LIVER FUNCTION TESTS BEFORE AND AFTER TREATMENT - 
OPATIENTS 
 
Sl. 
No 
 
OP NO 
SGOT 
(IU/dl) 
SGPT 
(IU/dl) 
Al.pho 
(U/dl) 
Albumin 
(g/dl) 
Globulin 
(g/dl) 
T. Protein 
(g/dl) 
BT AT BT AT BT AT BT AT BT AT BT AT 
21 H21084 18 19 19 22 82 92 3.0 3.1 3.4 3.2 6.4 6.3 
22 H21399 14 20 16 18 1z8 119 4.2 3.9 2.6 2.4 6.8 6.3 
23 H21836 22 24 26 24 73 112 3.8 3.7 3.5 2.9 6.3 6.4 
24 H22560 14 19 10 14 78 108 4.5 4.6 2.9 2.8 7.4 7.4 
25 H23059 14 15 11 12 73 87 4.0 4.1 2.3 2.3 6.3 6.4 
26 H23060 18 18 14 14 98 97 4.1 4.2 2.2 2.0 6.3 6.2 
27 H29115 17 16 14 13 88 89 4.8 4.7 2.2 2.6 7.0 7.3 
28 H29292 19 18 24 24 86 96 4.3 4.0 3.3 3.0 7.6 7.0 
29 H29300 22 28 25 2.3 87 98 4.1 4.1 2.7 2.6 6.8 6.7 
30 H29571 16 15 19 18 90 95 4.1 4.2 2.8 2.9 7.0 7.1 
31 H29914 19 20 14 15 75 82 4.3 4.2 3.5 2.6 7.8 6.8 
32 H35873 14 0 17 0 85 0 4.0 0 3.4 0 7.4 0 
33 H37384 17 18 19 20 92 97 3.8 3.7 2.6 1.9 6.4 5.7 
34 H41531 22 21 25 24 91 97 3.3 3.4 3.2 3.0 6.5 6.4 
35 H42222 15 16 21 20 115 114 3.2 3.1 3.1 2.0 6.3 5.1 
36 H45398 14 14 19 19 79 85 3.6 3.2 3.0 3.1 6.6 6.3 
37 H46888 16 15 24 25 106 102 3.4 3.2 3.0 2.9 6.4 6.1 
38 H47892 16 17 18 20 83 86 3.0 3.1 3.0 3.0 6.0 6.1 
39 H51842 14 15 16 15 85 87 3.1 3.0 2.7 2.6 5.8 5.6 
40 H52221 14 15 20 22 93 94 3.9 3.5 2.6 2.6 6.5 6.1 
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URINE EXAMINATION BEFORE AND AFTER TREATMENT – IP 
PATIENTS 
 
 
 
S. 
NO 
 
 
IP 
NO/OP 
NO 
URINE 
Before Treatment After Treatment 
Albumin Sugar 
Deposits 
Albumin Sugar 
Deposits 
Pus 
Cells 
Epi. 
cells 
Pus 
Cells 
Epi. 
cells 
1 7513 NIL NIL 1-2 2-3 NIL NIL 1-2 1-2 
2 7516 NIL NIL 1-2 3-4 NIL NIL 2-3 1-2 
3 7537 NIL NIL 2-3 4-5 NIL NIL 1-2 2-3 
4 7603 NIL NIL 1-2 1-2 NIL NIL 1-2 1-2 
5 7621 NIL NIL 3-4 1-2 NIL NIL 3-4 1-2 
6 7625 NIL NIL 1-2 2-3 NIL NIL 2-4 3-4 
7 7671 NIL NIL 2-3 1-2 NIL NIL 1-2 2-4 
8 7817 NIL NIL 2-3 1-2 NIL NIL 1-2 1-2 
9 7932 NIL NIL 3-5 3-4 NIL NIL 2-3 1-2 
10 7941 NIL NIL 2-3 2-4 NIL NIL 1-2 2-3 
11 H15914 NIL NIL 3-4 1-2 NIL NIL 1-2 3-4 
12 H16062 NIL NIL 4-5 1-2 NIL NIL 2-3 1-2 
13 H16214 NIL NIL 1-2 2-3 NIL NIL 2-3 2-3 
14 H16712 NIL NIL 1-2 1-2 NIL NIL 3-5 2-3 
15 H16756 NIL NIL 2-3 3-4 NIL NIL 2-3 3-5 
16 H16912 NIL NIL 1-2 1-2 NIL NIL 3-4 2-3 
17 H17115 NIL NIL 1-2 2-3 NIL NIL 4-5 1-2 
18 H19071 NIL NIL 3-4 2-3 NIL NIL 1-2 2-3 
19 H19442 NIL NIL 2-4 3-5 NIL NIL 1-2 3-4 
20 H19489 NIL NIL 3-5 2-3 NIL NIL 2-3 4-5 
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URINE  EXAMINATION BEFORE AND AFTER TREATMENT – OP 
PATIENTS 
 
 
 
S. 
NO 
 
 
OP  NO 
URINE 
Before Treatment After Treatment 
Albumin Sugar 
Deposits 
Albumin Sugar 
Deposits 
Pus 
Cells 
Epi. 
cells 
Pus 
Cells 
Epi. 
cells 
21 H21084 NIL NIL 2-3 2-3 NIL NIL 2-4 2-3 
22 H21399 NIL NIL 1-2 2-4 NIL NIL 1-2 1-3 
23 H21836 NIL NIL 2-4 1-2 NIL NIL 1-2 1-4 
24 H22560 NIL NIL 1-2 2-3 NIL NIL 4-5 2-5 
25 H23059 NIL NIL 1-2 1-3 NIL NIL 3-4 1-3 
26 H23060 NIL NIL 4-5 1-4 NIL NIL 2-4 1-2 
27 H29115 NIL NIL 3-4 2-5 NIL NIL 2-4 2-3 
28 H29292 NIL NIL 2-4 1-3 NIL NIL 2-3 2-3 
29 H29300 NIL NIL 2-4 1-2 NIL NIL 1-2 1-2 
30 H29571 NIL NIL 2-3 2-3 NIL NIL 1-2 2-4 
31 H29914 NIL NIL 1-2 2-3 NIL NIL 1-2 2-3 
32 H35873 NIL NIL 1-2 1-2 NIL NIL 4-5 1-2 
33 H37384 NIL NIL 2-3 2-4 NIL NIL 3-4 2-4 
34 H41531 NIL NIL 1-3 1-2 NIL NIL 2-4 1-2 
35 H42222 NIL NIL 1-4 1-2 NIL NIL 1-2 1-2 
36 H45398 NIL NIL 2-5 4-5 NIL NIL 1-2 1-3 
37 H46888 NIL NIL 1-3 3-4 NIL NIL 2-3 1-4 
38 H47892 NIL NIL 1-2 2-4 NIL NIL 1-3 2-5 
39 H51842 NIL NIL 2-3 2-4 NIL NIL 2-3 1-3 
40 H52221 NIL NIL 1-2 2-3 NIL NIL 1-2 1-2 
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STATISTICAL ANALYSIS 
All collected data were entered into MS Excel software using different 
columns as variables and rows as patients. SPSS software was used to perform 
statistical analysis. Basic descriptive statistics include frequency distributions and 
cross-tabulations were performed. The quantity variables were expressed as Mean ± 
Standard Deviation and qualitative data as percentage. A probability value of <0.05 
was considered to indicate as statistical significance. Paired‗t‘ test was performed for 
determining the significance between before and after treatment.  
 
Paired Sample Statistics (Pain BT and AT) 
Variable No Mean±Std T value P value 
BT 40 5.3±2.18  
13.32 
P<0.0001 
AT 40 0.75±1.64 
 
The mean± standard deviation of pain score at before and after treatment were 
5.3±2.18 and 0.75±1.6 4 respectively which is statistically significant . (t = 13.12                      
p <0.001).The % of reduction of pain is 85% from 5.3 to 0.75. 
Paired Sample Stastistics (ESR one hr BT and AT)) 
variable no mean±std T value P value 
BT 40 22±15.59 7.37 P<0.0001 
AT 40 7.05±6.00 
 
The mean± standard deviation of ESR at before and after treatment were 22±15.59 
and 7.05±6.00respectively which is statistically significant (t= 7.37 p <0.001).  The 
reduction of ESR in one hr is 68% from 22 to 7.05.  
 
 
 
 
 
 
 
 
  
Discussion 
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6. DISCUSSION 
 
 The main aim of the dissertation work is to study the therapeutic effect of the 
drug poora parpam in reducing the pain, swelling, restriction of movements 
and other clinical symptoms in the disesae Keel Vaayu.  
 
 The clinical features of Keel Vaayu can be correlated with Osteo Arthritis in 
modern science. OA is a degenerative joint disease involving the cartilage and 
many of its surrounding tissues. In addition to damage and loss of articular 
cartilage, there is remodelling of subarticular bone, osteophyte formation, 
ligamentous laxity, weakening of periarticular muscles and in some cases, 
synovial inflammation. 
 
 The drugs which possess anti-vatha property as mentioned in Siddha literature 
were selected and the trial drugs were prepared by the Author in the 
Gunapadam practical laboratory of  National Institute of Siddha, after getting 
proper authentication of raw drugs from the Medicinal botany department at 
NIS, Chennai 47, and Chemistry department in Siddha central Research 
Institute  Arumbakkam Chennai 106, under the supervision of the members of 
the teaching faculty and guided by the Head of the Department of  
Maruthuvam of the National Institute of Siddha, Chennai - 47. The trial drug 
was prepared by the standard operating procedure as mentioned in the 
protocol. 
 
 He safety Studies of  POORA PARPAM  has been completed as a Dissertation  
work at NIS(Referrence:Dissertation -187(D), DR.MGR MEDICAL 
UNIVERSITY reg no:32093606,April-2012 , Department of nanju noolum 
maruthuva neethu noolum,National Institute of Siddha, Chennai. reports 
showed no hepato and renal toxicity. 
 
 The trial drug was proved to be safe for human beings from the observations 
made from the study. 
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 The Biochemical qualitative and quantitative analysis were done at the 
Biochemistry lab of NIS, CCRS and IIT. It revealed the presence of effective 
minerals and the existence of the drug molecules at micro level.it also shows 
heavy metals are BDL(ICPOES). 
 
 The clinical study was conducted with a well defined protocol and a proper 
proforma after the approval of the Institutional Ethical Committee. After 
screening patients reporting at the OPD of department of Maruthuvam, 40 
cases were selected for induction to the trial. Before enrollment into the trial 
the informed consent was obtained from the patients. 
 
 40 patients of both genders were recruited for this study. Among the 40 
patients 30 were OPD patients and the remaining 10 were IPD patients. For In-
Patients, who were not in a situation to stay in the hospital for a long time, 
were advised to attend the Out-Patient Department of Maruthuvam for further 
follow- up.   
 
 The treatment was aimed at normalizing the deranged thodams and providing 
relief from symptoms. By giving purgation we can normalize the deranged 
Vaatham. 
“Å¢§ÃºÉò¾¡ø Å¡¾ó ¾¡Øõ” 
 
 Before treatment the patients were advised to take Agasthiyar kuzhambu- 130 
mg with notchi chaaru in early morning for purgation.The patient was advised 
to take rest without internal medicine on next day. 
 
 The patients were treated with trial drugs poora parpam 6 mg(internal) twice a 
day with butter or ghee and nathaichoori ennai Ennai 80ml (external) for 8 
days. Patients were instructed to take the medicines regularly advised to 
follow pathiyam (avoid tamarind, tubers, etc) and advised to avoid cold 
exposure. For Out- Patients the drugs were  given for 4 days followed by 4 
days of break ,again the medicine was given for 4 days. the clinical assessment 
was done on 0th day, and 12th day 
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 For In-Patients the drugs were given for 8 days and the clinical assessment 
was done daily. 
 After the treatment, the patients were advised to visit the Out-Patient ward of 
Department of Maruthuvam for another 2 months for follow-up. The results 
observed during the study period were discussed by the author below.   
 
OBSERVATIONS: 
 
 The majority affected sex is female (70%). The common cause for this may be 
depletion of calcium, nutritional deficiency, obesity and increased house hold 
works. History taking these reveals the above reasons for female 
predominance. 
 This study shows that the highest incidence of  keel vaayu is between 51-60 
years of age. 
 In this study, 75% of cases were reported from Neithal land. In Siddha 
literatures, it was mentioned that Neithal, which is responsible for Vaatha 
diseases. This study also emphasized the same. 
 Among 40 patients, 31 (75%) were non-vegetarians and 9 (25%) were 
vegetarians. 
 Munpani kaalam (Dec and Jan) showed the highest incidence of 62.5% and 
37.5% were reported during Pinpani kaalam. 
 Viyanan, Samanan were affected in all 40 cases.(patients had difficulties to 
flex and extend the knee) 
 In all the cases the Sathaga pitham was affected. 
 Santhigam was affected in all the 40 cases. Santhiga kabam mainly lives in 
joints and so it was affected in all the cases. 
 Pulse reading (Naadi) was observed in all patients. 30 cases had 
Vaathapitham, 8 cases had Pithavaatham, and Vaathakabam, Kabavaatham for 
each 1 cases. 
 Among 40 patients in 32 cases oil spreaded slowly, in 7 cases appeared like 
ring and in 1 cases it appeared like pearl. 
 Enbu was affected in all the 40 cases (100%), Saaram was also affected in all 
the 40 cases (100%), Kozhuppu was affected in all 40 cases (100 %), and there 
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were no changes noted in other thathukkal like Moolai, Sukkilam and 
Suronitham. 
 Kaal (leg) was affected in all the 40 cases (100%).(pain,swelling,movement 
restriction present in knee) 
 
CLINICAL MANIFESTATIONS: 
 Pain in the knee joint was present in 40 cases. Swelling was Present in 29 
cases. The other important features were morning stiffness in 14 cases, tenderness in 
22 cases, restricted movements in 40 cases, crepitation were observed in all 40 cases. 
 
PRECIPITATING FACTORS: 
 Already it was explained that aging is the most common cause for keel vaayu. 
Apart from that, increased household works, nutritional deficiency, Obesity (35%)and 
menopause, Hormonal imbalance were the other precipitating factors. 
 
OCCUPATIONAL REFERENCES: 
 Household work accounts for the highest number of 18 cases. More weight 
bearing and improper positioning of knee are also the cause which leads to 
Osteoarthritis. 
 
LABORATORY INVESTIGATIONS: 
 By laboratory investigation ESR was found raised in early stages but after 
treatment it was found reduced. 
 Total WBC counts, TRBC and Hb levels showed no changes in this study.. 
 Total cholesterol was decreased in considerable cases.  
 Blood Urea and Serum Creatinine levels showed no changes in this study. 
 The radiographic studies showed narrowed joint space and presence of 
Osteophytes. The trial drug showed improvement in prognosis of the disease 
clinically rather than in radiographic changes. 
 
TREATMENT: 
 The treatment was aimed at normalizing the deranged mukkutram and 
providing relief from symptoms. As the first line of treatment patients were given 
97 
 
purgation with Agasthiyar kulambu - 130mg with notchi charu in the early morning. 
The patient was advised to take rest without internal medicine on that day. 
 Then the author treated the patients with trial drugs POORA PARPAM 6 mg 
bid ghee or butter (Internal) and nathai choori ennai (External). During treatment, the 
patients were advised to follow Pathiyam (avoid tamarind, tubers.etc.). Drugs were 
given for 4 days followed by 4 days of break; again the medicine was given for 4 days 
 
EFFECT OF TREATMENT: 
 Good improvement was observed in 30 Patients, moderate improvement in 6 
patients and mild improvement in 4 patients. The mean pain score before treatment 
was 5.3 and after treatment it is reduced to 0.75.No toxic and side effects were 
clinically observed in all cases. 
 
EVALUATION OF MEDICINES: 
 
 The preliminary phytochemical study revealed the presence of several phyto-
constituents. The test drug answered for the presence of Amino acid, calcium, 
Tannic Acid and Alkaloids. 
 The biochemical markers of liver function test did not show any evidence of 
liver toxicity. 
 The biochemical markers of renal function test did not show any evidence of 
renal toxicity. 
 There were no significant changes in biochemical parameters like blood 
cholesterol, body weight, food, water intake and behavioral parameters. 
 
 
 
 
 
 
 
 
 
  
Summary 
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7. SUMMARY 
 
 This study has been approved by IEC of NIS [IEC approved no:NIS/IEC /8-
14/5- 26-08-2014. 
 The clinical study on keel vaayu with reference to its aetiology, pathogenesis, 
investigations, clinical features, diagnosis and treatment were conducted at the 
department of maruthuvam, Ayothidoss Pandithar Hospital, National Institute 
of Siddha, Chennai – 47. 
 The required raw drugs for the preparation of POORA PARPAM (internal) 
and NATHAICHOORI ENNAI(external)  were  purchased from a well 
reputed country shop and the raw drugs will be authenticated in concern 
department ( Department Medicinal botany,  NIS and SCRI  and purified. The 
medicine was prepared in Gunapadam laboratory of National institute of 
Siddha. 
 Drugs were prepared by the Author in the Gunapadam practical laboratory of 
National Institute of Siddha 
 40 cases of both the sexes (majority of females) with the signs and symptoms 
of  keel vaayu were selected in the age group within 30 to 60 for the study. 10 
In-Patients were given the trial drugs each for 8 days. 30 cases were treated in 
the Out- Patient Department each for 8 days with the trial drugs. 
 All the details about the study and the drugs were informed to the patients in 
their vernacular language, dietary regimen and information sheet were given 
to them and signed consent forms were obtained from them. Before starting 
the treatment, the blood samples of the selected patients were subjected to 
clinical laboratory and radiological investigation. 
 On the first day of the treatment, purgation was given by administering 
Agasthiyar kulambu – 130mg with notchi chaaru in the early morning to 
normalize the deranged  vadham humour. 
 Second day the patient were put under rest. 
 From the third day onwards, the patients were treated with the trial drugs 
poora parpam 6 mg bid with ghee or butter was given internally and 
nathaichhori ennai.Every 4
th
 day; the patients were assessed for clinical 
improvement and adverse effects.  
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 Before treatment (0th day) and at the end of the treatment (12th day) the 
laboratory investigations were done. The x-ray of the affected Joints was 
taken. The improvement was assessed. 
 During the course of treatment there were no adverse effects or unwanted drug 
reactions in Gastro intestinal tract, Respiratory system, Cardio vascular system 
and excretory systems. 
 The safety Studies of  POORA PARPAM  has been completed as a 
Dissertation  work at NIS(Referrence:Dissertation -187(D), DR.MGR 
MEDICAL UNIVERSITY reg no:32093606,April-2012 , Department of nanju 
noolum maruthuva neethu noolum,National Institute of Siddha, Chennai. 
reports showed no hepato and renal toxicity. 
 The study results showed that 75 % had Good improvement, 15% had 
Moderate improvement and 10% had mild improvement. The pain assessment 
was done in all the 40 patients participated in the trial using the universal pain 
assessment scale and at the end of the study the results showed, the mean pain 
score before treatment was 5.3 and after treatment it is reduced to 0.75. The 
restriction of movements after treatment was reduced in 30 cases and persists 
in 10 cases. 
 
 
 
 
 
 
 
 
 
 
   
Conclusion 
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8.CONCLUSION 
 The study results showed that 75 % had Good improvement, 15 % had 
Moderate improvement and 10 % had mild improvement. 
 The safety Studies of  POORA PARPAM  has been completed as a 
Dissertation  work at NIS(Referrence:Dissertation -187(D), DR.MGR 
MEDICAL UNIVERSITY reg no:32093606,April-2012 , Department of nanju 
noolum maruthuva neethu noolum,National Institute of Siddha, chennai-47. 
The trial drug was proved safe. 
 Clinically, no adverse effects were reported during the trial and the laboratory 
investigations were also within normal limits. So, the drug is assumed to be 
safe for humans 
 Hence the study concludes that, the trial drugs are clinically effective in 
reduction of pain, swelling, restriction of movements.  
 Because of the encouraging clinical results, it could be concluded that 
―POORA PARPAM” (Internally)‖ and ―NATHAICHOORI ENNAI 
(Externally)‖ are effective in the treatment of ―keel vaayu‖ (Osteoarthritis). 
 However further work with large number of patients should be carried out 
towards finding the ideal dose response. 
 
 
 
 
  
  
Annexures 
 
  
  
Proforma 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
POST-GRADUATE DEPARTMENT OF  MARUTHUVAM 
 
CLINICAL EVALUATION OF SIDDHA DRUG, POORA PARPAM (Internal) 
NATHAICHOORI ENNAI (External)IN THE TREATMENT OF   
KEELVAYU(OSTEOARTHRITIS) 
Principal Investigator:                                                               Reg. No:  
     FORM I - SCREENING & SELECTION PROFORMA 
1. SERIAL NO :                             2.  OP /IP NO: -------------                              
3. NAME: ……………………………………     4. AGE/GENDER: ………….......   
5. OCCUPATION: ……………………      6. INCOME:   ………………… 
INCLUSION CRITERIA 
 Whether age is between 30-60                                  YES\ NO  
 Sex-Both                             M \ F 
 Pain @ swelling of both knee joints.               YES\ NO  
 crepitations                                                                              YES\ NO  
 stiffness @ restricted movements                                                 YES\ NO  
 willing to attend OPD or admission in IPD for the trial   YES\ NO 
 Willingness for consent       YES\ NO 
 Willing to give specimen of blood for the investigation     YES\ NO 
 willing to undergo radiological investigation                            YES\ NO 
EXCLUSION CRITERIA 
 Hypertension         YES\ NO 
 Diabetes mellitus       YES\ NO 
 Cardiac disease        YES\ NO  
 Rheumatoid arthritis       YES\ NO 
 Tuberculosis                  YES\ NO 
 Patient with any other serious systemic illness   YES\ NO 
 Chronic kidney disease                                                                YES\ NO 
 Gouty arthritis                                                                            YES\ NO 
ADMITTED TO TRAIL 
YES  NO  
If Yes, OPD  IPD  
    
Date:        
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                        Signature of the HOD   
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
POST-GRADUATE DEPARTMENT OF  MARUTHUVAM 
 
CLINICAL EVALUATION OF SIDDHA DRUG, POORA PARPAM (Internal) 
NATHAICHOORI ENNAI(External)IN THE TREATMENT OF   
KEELVAYU(OSTEOARTHRITIS) 
 
Principal Investigator:                                                               Reg. No:  
 
FORM II –A 
 
STUDY  NO:   OP / IP NO: 
NAME: AGE / GENDER: 
ADDRESS: CONTACT NO : 
 RELIGION :  H / C / M / O. 
OCCUPATION: INCOME: 
MARITAL STATUS :       1. Married 2. Unmarried 
DATE OF INTIAL ASSESSMENT:  
COMPLAINTS & DURATION:   
                                                                                                                                                                                
PERSONAL HISTORY: 
PERSONAL HABITS YES NO 
IF YES 
SPECIFY 
DURATION 
AMOUNT/Qty 
Smoking     
Tobacco Chewing     
Alcohol     
Narcotic  Drug Addiction     
  
 
HISTORY OF PREVIOUS ILLNESS AND TREATMENT TAKEN: 
 
FAMILY HISTORY:  
Whether this problem runs in family? 1. Yes            2. No    
If yes, mention the relationship of affected 
person(s) 
1._________________ 
 
2._________________ 
 
DIETARY STYLE: 1. Vegetarian    2. Non-vegetarian 
MENSTURAL AND OBSTETRIC  
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HISTORY: 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                       Signature of the HOD 
 
 
 
FORM –II B 
GENERAL EXAMINATION: 
1. Body weight [Kg]    :                      
2. Height [cms]                       :                        
3. Body Temperature [F]       :   
4. Blood Pressure (mm/Hg)  :      
5. Pulse Rate /min.        : 
6. Heart Rate / min.         : 
7. Respiratory Rate /min.  :   
                                                                                  Yes            No   
8. Pallor   :   
9. Jaundice   :   
10. Clubbing   : 
11. Cyanosis   : 
12. Pedal Oedema   : 
13. Lymphadenopathy            :                                        
14. Jugular venous pulsation   :   
SYSTEMIC EXAMINATION 
  Cardiovascular system  :  
  Respiratory system   :  
  Gastro-intestinal system  :  
  Central Nervous system  :  
  Urogenital system   :  
  Endocrine system             :  
SIDDHA SYSTEM OF EXAMINATION 
1. THEGI (BODY CONSTITUTION): 
1. Vatha udal 
2. Pitha udal 
3. Kaba udal 
4. Thontha udal 
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2. NILAM (LAND WHERE THE PATIENT LIVED MOST):  
1. Kurinji (Hilly terrain) 
2. Mullai (Forest range) 
3. Marutham (Plains) 
4. Neithal (Coastal belt) 
5. Paalai (Aridregion) 
3. KAALAM: 
1. Kaar kaalam    (Aavani-Purattasi) 
2. Koothir kaalam     (Ippasi-Kaarthigai) 
3. Munpani kaalam     (Maargazhi-Thai) 
4. Pinpani kaalam       (Maasi-Panguni) 
5. Ilavenil kaalam        (Chithirai-Vaigasi) 
6. Muthuvenil kaalam (Aani-Aadi) 
 
4. GUNAM: 
1. Sathuvam  
2. Rasatham 
3. Thamasam 
 
5. PORIPULANGAL (SENSORY ORGANS):          
                  
  
 
 
 
 
 
 
 
6.KANMENDRIYAM (MOTOR ORGANS) : 
        
 
 
 
 
 
 
 
 
 
 
 Before treatment After treatment 
Mei (Skin) Normal  / Affected Normal  / Affected 
Vai (Tongue) Normal  / Affected Normal  / Affected 
Kann (Eye) Normal  / Affected Normal  / Affected 
Mooku (Nose) Normal  / Affected Normal  / Affected 
Sevi (Ear) Normal  / Affected Normal  / Affected 
 Before treatment After treatment 
Kai  Normal  /Affected Normal  /Affected 
Kaal  Normal  /Affected Normal  /Affected 
Vai    Normal  /Affected Normal  /Affected 
Eruvai  Normal  /Affected Normal  /Affected 
Karuvai  Normal  /Affected Normal  /Affected 
105 
 
7. KOSANGAL (SHEATH):                
 
 
 
 
 
 
  
   
8. SEVEN UDAL THAATHUKKAL (SEVEN SOMATIC COMPONENTS) 
 
 Before treatment After treatment 
Saaram Normal  /Affected Normal  /Affected 
Senneer  Normal  /Affected Normal  /Affected 
Oon Normal  /Affected Normal  /Affected 
Kozhuppu Normal  /Affected Normal  /Affected 
Enbu Normal  /Affected Normal  /Affected 
Moolai Normal  /Affected Normal  /Affected 
Sukkilam / Suronitham Normal  /Affected Normal  /Affected 
 
A) VALI:  
 
 
 
 
0
th
 
day 
12
th
day 
Praanan   
Abaanan   
Samaanan   
Udhaanan   
Viyaanan   
Naagan   
Koorman   
Kirukaran   
Devathathan   
Dhananjeyan   
 Before treatment After treatment 
Annamaya kosam Normal  /Affected Normal  /Affected 
Pranamaya kosam  Normal  /Affected Normal  /Affected 
Manomaya kosam  Normal  /Affected Normal  /Affected 
Vignanamaya kosam  Normal  /Affected Normal  /Affected 
Ananthamaya kosam Normal  /Affected Normal  /Affected 
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B) AZHAL 
 
 0
th
 day 
12
th
 
day 
Analakam   
Ranjakam    
Saathakam    
Prasakam    
Aalosakam   
 
 
C) IYYAM 
 
 0
th
 day 12
th
day 
Avalambagam   
Kilethagam   
Pothagam   
Tharpagam   
Santhigam   
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10. ENVAGAI THERVU: [EIGHT TYPES OF EXAMINATION] 
 
I. NAADI: [PULSE PERCEPTION] 
 
NAADI 0
th
  day 
 
           12
th
day  
 
II. SPARISAM: [PALPATION] 
 
Day SPARISAM 
0
th
  day  
12th  day  
 
 
III. NAA: [TONGUE] 
 
NAA 0
th
day 12 
th
day 
   
 
 
IV. NIRAM: [COMPLEXION]   
    1. Vadham         
     2. Pitham 
      3. Kabam  
 
 
V. MOZHI: [VOICE] 
      1. High Pitched 
      2. Low Pitched 
      3. Medium Pitched 
 
 
VI.VIZHI: [EYES] 
 
VIZHI 0
th
  day 12
th
 day 
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VII. MALAM: [BOWEL HABITS / STOOLS] 
 
 Before treatment After treatment 
Niram   
Irugal   
Ilagal   
Others   
 
 
VIII. MOOTHIRAM [URINE EXAMINATION]  
NEERKKURI: 
 
Neerkkuri Before treatment After treatment 
Niram   
Manam   
Edai   
Nurai   
Enjal   
 
 
NEIKKURI:  
 
Neikkuri Before treatment After treatment 
 Aravana needathu/ 
Snake like pattern 
 
  
Azhipol paraviyathu 
Annular/Ringedpattern 
 
 
 
parav 
paraparavoiyadu 
  
Muththothu ninrathu  
Pearlbeadepattern 
  
Other patterns   
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NATIONAL INSTITUTE OF SIDDHA. 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
POST-GRADUATE DEPARTMENT OF  MARUTHUVAM 
 
An open clinical trial to Evaluate the Therapeutic Efficacy of Siddha  formulation 
POORA PARPAM (Internal) and NATHAICHOORI ENNAI (External) in the 
management of KEEL VAYU (OSTEOARTHRITIS). 
 
Principal Investigator:                                                               Reg. No:  
 
FORM    : CLINICAL ASSESSMENT DURING & AFTER TRIAL 
1. OP/ IP NO: …………  2. SL. NO: ………  3.NAME: ………………………….          
4. AGE: ………  5. GENDER: …...   6. DATE OF RECRUITMENT: …… 
12. CLINICAL EXAMINATION:  
13. LOCOMOTOR SYSTEM: 
 CLINICAL SYMPTOMS: 
Affected knee joints: Right Left    Both               
Pain in knee joint: Mild Moderate   Severe 
Onset:                         Sudden                   Gradual 
14. CLINICAL EXAMINATION OF KNEE JOINT   
I.INSPECTION: 
 0
th
 day 12
th
day 
Attitude   
swelling   
Skin over the knee joints   
Muscle wasting   
Deformity   
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II.PALPATION: 
 0
th
 day 12 day 
Tenderness   
Crepitation   
Local heat   
 
III. MOVEMENTS 
 0
th
 day 12
th
 day 
Flexion   
Extension   
 
IV. JOINT MESUREMENT: 
A.  
 
 
 
 
 0
th
 day 12 
th
day 
PAIN 
A. Onset: Sudden/Gradual 
  
B. Early morning  Stiffness 
(Present/absent) 
  
C. Nature of pain                                             
(Mild/ Moderate/ Severe) 
  
D. Aggravating   factor- Movement  
(Yes/No) 
  
E. Relieving factor – Rest(Yes/No)   
G. Tenderness (Present/absent)   
RESTRICTION OF MOVEMENT  
(Fully/Partial/No) Knee joints 
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B. UNIVERSAL PAIN ASSESMENT SCALE:
 
 
   0    :  No Pain 
  1 -3 :   Mild pain 
  4-6 :   Moderate pain 
            7-9     :           Severe pain     
 10       :         worst possible pain                    
 
C. RESTRICTED MOVEMENT ASSESSMENT SCALE:                
Gradation of movements: 
 Grade 1 - Fit for all activities, do their work without support. 
 Grade II - Mild pain present in knee joint, mild restricted movements. 
 Grade III - Pain present in knee joint, moderate restriction of movements. 
 Grade IV - Severe pain, bed ridden. 
 
(Ref: Clinical manual for nursing practice (National Institute of Health Warren 
Grant Magnuson Clinical Centre) 
 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                       Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
POST-GRADUATE DEPARTMENT OF  MARUTHUVAM 
 
CLINICAL EVALUATION OF SIDDHA DRUG,POORA PARPAM (Internal) 
NATHAICHOORI ENNAI(External)IN THE TREATMENT OF   
KEELVAYU(OSTEOARTHRITIS) 
 
Principal Investigator:                                                               Reg. No:  
 
.FORM-III - LABORATORY INVESTIGATIONS 
 
 
 
BLOOD INVESTIGATIONS 
NORMAL 
VALUES 
BEFORE 
TREATMENT 
AFTER 
TREATMENT 
Hb( gm/dl) 
M:13-18 
W:11-16 
  
T.RBC(millions cells /Cu.mm) 
M:4.5-6.5 
W:3.5-5.5 
  
ESR (mm) 
½ hr. -   
1 hr. 
M:0-10 
W:0-20 
  
T.WBC (Cells /Cu.mm) 4000-11000   
Differential 
Count (%) 
Polymorphs 40-75   
Lymphocytes 20-35   
Monocytes 2-10   
Eosinophils 1-6   
Basophils 0-1   
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BLOOD INVESTIGATIONS 
NORMAL 
VALUES 
BEFORE 
TREATMENT 
AFTER 
TREATMENT 
Blood 
glucose 
(mg/dl) 
Fasting 70-110   
PP 80-140   
Lipid 
profile 
(mg/dl) 
Serum cholesterol 150-200   
HDL 30-60   
LDL Up to 130   
VLDL 40   
TGL Up to 160   
RFT 
(mg/dl) 
Blood urea 16-50   
Serum creatinine 0.6-1.2   
LFT 
(mg/dl) 
Total bilirubin 0.2-1.2   
Direct bilirubin 0.1-0.2   
Indirect bilirubin 0.2-0.7   
Total protein 6-8   
Serum Albumin 3.5-5.5   
Serum globulin 2-3.5   
SGOT (IU/L) 0-40   
SGPT (IU/L) 0-35   
Alkaline phosphatase 
(IU/L) 
80-290   
 
Serum calcium 9-11   
Serum phosphorus 2-5   
Serum Uric acid 
M:3-9 
W: 2.5-7.5 
  
 CRP   
 ASO titre   
 RA factor   
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B.URINE INVESTIGATIONS: 
URINE 
INVESTIGATIONS 
BEFORE TREATMENT 
AFTER 
TREATMENT 
Albumin   
Sugar (Fasting) 
        (PP) 
  
Deposits   
Bile salts   
Bile pigments   
 
  
 
C.RADIOLOGICAL EXAMINATIONS 
X- Ray: Knee joint: 
1. Antero posterior  
2. Lateral view 
 
 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                       Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
POST-GRADUATE DEPARTMENT OF MARUTHUVAM 
An open clinical trial to Evaluate the Therapeutic  Efficacy of Siddha formulation 
POORA PARPAM (Internal) and NATHAICHOORI ENNAI (External) in the 
management of KEEL VAYU (OSTEOARTHRITIS). 
Name of Principal Investigator:     Reg. No : 
FORM  - IV(DRUG COMPLIANCE FORM) 
SERIAL NO: 
NAME:  
DRUG NAME  
On 1
st    
 day-Date:  Drugs issued:                     Drugs returned:     
On 9
th
   day-Date:   Drugs issued:                   Drugs returned:  
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                        Signature of the HOD 
 
  
   Day    Date    Morning   Evening 
Day 1    
Day2    
Day3    
Day4    
Day9    
Day10    
Day11    
Day12    
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FORM  – PATIENT INFORMATION SHEET 
 
Name of Principal Investigator:     Reg. No : 
 
Name of the institute: National Institute of Siddha, 
                                      Tambaram Sanatorium, 
                                      Chennai-47. 
 
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN 
CLINICAL TRIAL. 
 
I,……………Studying M.D (Siddha) at National Institute of Siddha, 
Tambaram Sanatorium is doing a trial on KEEL VAYU (OSTEOARTHRITIS). Osteo 
arthritis is a most common degenarative disease, occurring throughout the world. In 
this regard, I am in a need to ask you few questions. I will maintain confidentiality of 
your comments and data obtained. There will be no risk of disclosing your identity 
and no physical, psychological or professional risk is involved by taking part in this 
study. Taking part in this study is voluntary. No compensation will be paid to you for 
taking part in this study. 
 
           You can choose not to take part. You can choose not to answer a specific 
question. There is no specific benefit for you if you take part in the study. However, 
taking part in the study may be of benefit to the community, as it may help us to 
understand the problem of defaulters and potential solutions. 
 
             If you agree to be a participant in this study, you will be included in the study 
primarily by signing the consent form and then you will be given the internal 
medicine POORA  PARPAM  (Internal medicine- 6mg BD with ghee or butter for 8 
days) and NATHAICHOORI ENNAI 80ml(External  medicine), if you wish to stay in 
the InPatient ward Treatment will be provided to you assuring that you will not be 
definitely hurt in any course of treatment. 
 
  The information I am collecting in this study will remain confidential.  
 
If you wish to find out more about this study before taking part, you can ask 
me all the questions you want or contact Dr.G.KARPAGAM PG Scholar  principal 
investigator of this study, attached to National Institute of Siddha, Chennai-47. You 
can also contact the Member-secretary of Ethics committee, National Institute Siddha, 
Chennai 600047, Tel No: 9940050581, for rights and participation in the study. 
        
 
 
 
 
117 
 
¾¸Åø  ÀÊÅõ 
 
"¸£ø Å¡Ô §¿¡öì¸¡É º¢ò¾ ÁÕóÐ¸Ç¢ý âÃ  ÀüÀõ (¯û ÁÕóÐ) ÁüÚõ  
¿ò¨¾ÝÃ¢ ±ñ¦½ö (¦ÅÇ¢ ÁÕóÐ) ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ 
ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ. 
 
Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ¦ÀÂ÷  :  ÁÕ.§¸¡.¸üÀ¸õ 
¿¢ÚÅÉò¾¢ý ¦ÀÂ÷            :  §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
                                ¾¡õÀÃõ º¡Éð§¼¡Ã¢Âõ 
                                ¦ºý¨É- 47 
 
§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉò¾¢ø Àð¼ §ÁüÀÊôÒ ÀÂ¢ýÚ ÅÕõ ¿¡ý  
(ÁÕòÐÅ÷..§¸¡.¸üÀ¸õ.) "¸£øÅ¡Ô ±ýÛõ ãðÎ¸¨Ç À¡¾¢ìÌõ §¿¡öì¸¡É 
ÁÕòÐÅ ¬Ã¡öîº¢Â¢ø ®ÎÀðÎû§Çý.               
¸£øÅ¡Ô ±ýÛõ §¿¡Â¡ÉÐ ±ÖõÒ §¾öÁ¡Éò¾¡Öõ ±ÖõÒ¸ÙìÌ þ¨¼§Â 
þ¨¼¦ÅÇ¢ Ì¨ÈÅ¾¡Öõ ÓÆí¸¡ø ãðÎ¸Ç¢ø ¯ûÇ ¦¿öôÒò¾ý¨Á 
Ì¨ÈÅ¾¡Öõ ¯ñ¼¡¸¢ÈÐ. þÐ ÓÆí¸¡ø ãðÎ¸Ç¢ø ÅÄ¢, Å£ì¸õ, 
ãðÎ¸¨Ç ¿£ð¼ Á¼ì¸ º¢ÃÁõ,¿¼ôÀ¾¢ø º¢ÃÁõ,¸¡¨Ä §¿Ãí¸Ç¢ø 
Å¢¨ÈôÒò¾ý¨Á Ó¾Ä¢Â ÌÈ¢Ì½í¸¨Çì ¦¸¡ñ¼ §¿¡ö 
þÐ ÀÃÅì ÜÊÂ §¿¡ö "«øÄ. 
þó¾ ¬Ã¡öîº¢ ºõÀó¾Á¡¸ º¢Ä §¸ûÅ¢¸¨Çì §¸ð¸×õ, §¾¨ÅÂ¡É ¬öÅ¸ 
ÀÃ¢§º¡¾¨ÉìÌ ¾í¸¨Ç ¯ðÀÎò¾×õ ¯û§Çý. 
 
þó¾ ¬Ã¡öîº¢ìÌ ¾¡í¸û Å¢ÕôÀò¾¢ý §ÀÃ¢ø ¯ðÀÎõ Àðºò¾¢ø 
¯ûÁÕó¾¡¸  âÃ  ÀüÀõ (6mg) 2 §Å¨Ç  (¸¡¨Ä Á¡¨Ä) ¯½×ìÌô À¢ý 8 
¿¡ð¸ÙìÌ ¯ð¦¸¡ûÇ §ÅñÎõ. ¦ÅÇ¢ ÁÕó¾¡¸ ¿ò¨¾ÝÃ¢ ±ñ¦½ö 10 
Á¢Ä¢ 8 ¿¡ð¸ÙìÌ §¿¡ÔûÇ þ¼í¸Ç¢ø ¦ÅÇ¢§Â ¾¼Å §ÅñÎõ. ¦ÅÇ¢ 
§¿¡Â¡Ç÷ 4 ¿¡ð¸ÙìÌ ´ÕÓ¨È ÁÕòÐÅÁ¨ÉìÌ ÅÃ§ÅñÎõ.  
þÐ ºõÀó¾Á¡É ¾í¸ÇÐ "«¨ÉòÐ Å¢ÅÃí¸Ùõ Ã¸º¢ÂÁ¡¸ ¨Åì¸ôÀÎõ 
±É ¯Ú¾¢ «Ç¢ì¸¢§Èý. þ¾¢ø ÀÂ½ôÀÊ Ó¾Ä¢Â ±ó¾ ¯¾Å¢ ¦¾¡¨¸Ôõ 
ÅÆí¸ôÀ¼ Á¡ð¼¡Ð. þó¾ Ã¡öîº¢Â¢ý §À¡Ð ¯¼ÖìÌ §ÅÚ À¡¾¢ôÒ ²üÀÎõ 
Àðºò¾¢ø §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø ¾ì¸ Á¡üÚ º¢¸¢î¨º ¬Ç¢ì¸ôÀÎõ. 
þó¾ ¬Ã¡öîº¢Â¢ø ¾í¸¨Ç ¯ðÀÎò¾¢Â À¢ÈÌ ¯í¸ÙìÌ 
Å¢ÕôÀÁ¢ø¨Ä¦ÂÉ¢ø ±ô§À¡Ð §ÅñÎÁ¡É¡Öõ Å¢Ä¸¢ ¦¸¡ûÇ ÓØ ¯Ã¢¨Á 
¯ûÇÐ. 
 
þó¾ ¬Ã¡öîº¢ ºõÀó¾Á¡¸ ÁüÈ Å¢ÀÃí¸ÙìÌõ §¿¡Â¢ý ¾ý¨Á 
ÀüÈ¢Ôõ  Ó¾ý¨Á ¬Ã¡öîº¢Â¡ÇÃ¡É ÁÕ.§¸¡.¸üÀ¸õ  (Àð¼ §Áü ÀÊôÀ¡Ç÷ 
º¢ÈôÒ ÁÕòÐÅ À¢Ã¢×) "«Ï¸×õ. ¨¸ô§Àº¢ ±ñ 9940050581 §ÁÖõ þó¾ 
¬Ã¡öîº¢ìÌ IEC º¡ýÚ ¦ÀÈôÀðÎûÇÐ. 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
POST-GRADUATE DEPARTMENT OF  MARUTHUVAM 
  
CLINICAL EVALUATION OF SIDDHA DRUG,POORA PARPAM (Internal) 
NATHAICHOORI ENNAI(External)IN THE TREATMENT OF   
KEELVAYU(OSTEOARTHRITIS) 
 
Name of Principal Investigator:     Reg. No :  
 
CONSENT FORM    -   FORM  
 
“I have read the foregoing information, or it has been read to me. I have 
had the opportunity to ask questions about it and any questions I have asked have 
been answered to my satisfaction.  
            I consent voluntarily to participate as a participant in this study and 
understand that I have the   right to withdraw from the study at any time without in 
any way it affecting my further medical care”. 
 
"I have received a copy of the information sheet/consent form". 
 
Date:  
Signature of the participant 
In case of illiterate participant 
 
        “I have witnessed the accurate reading of the consent form to the potential 
participant, and the individual has had the opportunity to ask questions. I confirm 
individual has given consent freely.”                                                   
 
 
Date: 
 
 
Signature of a witness  
(Selected by the participant bearing no connection with the survey team)  
        
          
            
 
 
 
Left thumb Impression of the Participant 
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FORM  ´ôÒ¾ø ÀÊÅõ 
 
¬öÅ¡ÇÃ¡ø º¡ýÈÇ¢ì¸ôÀð¼Ð 
 
¿¡ý ¸£ø Å¡Ô ±ýÛõ §¿¡Â¢ý ¬ö¨Åì ÌÈ¢ò¾ «¨ÉòÐ 
Å¢ÀÃí¸¨ÇÔõ §¿¡Â¡Ç¢ìÌô ÒÃ¢Ôõ Å¨¸Â¢ø ±ÎòÐ¨Ãò§¾ý ±É 
¯Ú¾¢ÂÇ¢ì¸¢§Èý. 
 
 
§¾¾¢:                                        ¨¸¦Â¡ôÀõ: 
                     
þ¼õ:                 ¦ÀÂ÷:                                                
                                         
 
§¿¡Â¡Ç¢Â¢ý ´ôÒ¾ø 
 
±ýÉ¢¼õ  þó¾  ÁÕòÐÅ  ¬öÅ¢ý  ¸¡Ã½ò¨¾Ôõ,  ÁÕó¾¢ý 
¾ý¨Á  ÁüÚõ ÁÕòÐÅ  ÅÆ¢Ó¨È  ÀüÈ¢Ôõ, ¦¾¡¼÷óÐ  ±ÉÐ  ¯¼ø  
þÂì¸ò¨¾ì  ¸ñ¸¡½¢ì¸×õ, «¾¨Éô  À¡Ð¸¡ì¸×õ  ÀÂýÀÎõ  ÁÕòÐÅ  
¬ö×ìÜ¼  ÀÃ¢§º¡¾¨É¸û  ÀüÈ¢  ¾¢Õô¾¢ «Ç¢ìÌõ  Å¨¸Â¢ø  ¬ö×  
ÁÕòÐÅÃ¡ø  Å¢Çì¸¢ì  ÜÈôÀð¼Ð. 
 
¿¡ý  þó¾  ÁÕòÐÅ  ¬öÅ¢ý  §À¡Ð, ¸¡Ã½õ  ±Ð×õ  ÜÈ¡Áø, 
±ô¦À¡ØÐ §ÅñÎÁ¡É¡Öõ  þó¾  ¬öÅ¢Ä¢ÕóÐ   ±ý¨É Å¢ÎÅ¢òÐ  
¦¸¡ûÙõ  ¯Ã¢¨Á¨Âò ¦¾Ã¢ó¾¢Õì¸¢ý§Èý. 
 
¿¡ý  ±ýÛ¨¼Â  Í¾ó¾¢ÃÁ¡¸ò  §¾÷×  ¦ºöÔõ  ¯Ã¢¨Á¨Âì  
¦¸¡ñÎ  ¸£ø Å¡Ô ±ýÛõ §¿¡öìÌ âÃ  ÀüÀõ (¯û ÁÕóÐ) ÁüÚõ 
¿ò¨¾ÝÃ¢ ±ñ¦½ö (¦ÅÇ¢ ÁÕóÐ)  ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò  ¾¢È¨Éì  
¸ñ¼È¢Ôõ  ÁÕòÐÅ  ¬öÅ¢üÌ  ±ý¨É  ¯ðÀÎò¾ ´ôÒ¾ø  «Ç¢ì¸¢§Èý. 
 
 
§¾¾¢:                                    ¨¸¦Â¡ôÀõ: 
þ¼õ:             ¦ÀÂ÷:         
                                        º¡ðº¢ì¸¡Ã÷ ¦ÀÂ÷:                           
  ¨¸¦Â¡ôÀõ: 
                    ¯È×Ó¨È:     
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
POST-GRADUATE DEPARTMENT OF  MARUTHUVAM 
 
CLINICAL EVALUATION OF SIDDHA DRUG,POORA PARPAM (Internal) 
NATHAICHOORI ENNAI(External)IN THE TREATMENT OF   
KEELVAYU(OSTEOARTHRITIS) 
 
Name of Principal Investigator:     Reg. No : 
 
FORM  - WITHDRAWAL FORM 
 
1. SERIAL NO OF THE CASE: …………………   
2. OP / IP NO: ......................................    
3. NAME: ………………………     
4.AGE: …………        
5.GENDER:...........                           
6. DATE OF TRIAL COMMENCEMENT: ………………... 
7. DATE OF WITHDRAWAL FROM TRIAL: …………….. 
8. REASONS FOR WITHDRAWAL: 
Long absence at reporting:               Yes/ No 
Irregular treatment:                           Yes/ No 
Shift of locality:                                     Yes/No 
Increase in severity of symptoms:     Yes/No 
Development of severe adverse drug reactions:   Yes/No 
Development of  adverse event :                                            Yes/No 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                        Signature of the HOD 
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                         NATIONAL INSTITUTE OF SIDDHA 
          AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
POST-GRADUATE DEPARTMENT OF  MARUTHUVAM 
 
An open clinical trial to Evaluate the Therapeutic  Efficacy of Siddha Herbo-mineral 
formulation POORA PARPAM (Internal) and NATHAICHOORI ENNAI 
(External) in the management of  KEEL VAYU (OSTEOARTHRITIS). 
 
Name of Principal Investigator:     Reg. No :  
 
FORM –ADVERSE REACTION FORM 
 
SERIAL NO:                                                                                                           
OP/IP NO: 
NAME:                                                             AGE:                     GENDER: 
DATE OF TRIAL COMMENCEMENT: 
DATE OF THE ADVERSE REACTION OCCUR: 
DESCRIPTION OF ADVERSE REACTION: 
 
 
 
Date:                                                                              
Station:  
Signature of the Investigator: 
Signature of the Lecturer:                                                            Signature of the HOD 
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NATIONAL PHARMACOVIGILANCE PROGRAMME FOR  SIDDHA DRUGS 
 
 
 
 
Please note:  i.  All consumers / patients and reporters information will remain 
confidential. 
ii. It is requested to report all suspected reactions to the concerned, 
even if  
it does not have complete data, as soon as possible. 
Peripheral Center code:     State:  
 
1. Patient / consumer identification (please complete or tick boxes below as 
appropriate) 
Name  Father name 
 
Patient / Record No. 
Ethnicity  Occupation 
Address  
Village / Town 
Post / Via 
District / State    
Date of Birth / Age: 
 
Sex:     Male / Female  
Weight : 
Degam: 
 
 
 
 
 
 
Reporting Form for Suspected Adverse Reactions to Siddha Drugs 
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2. Description of the suspected Adverse Reactions (please complete boxes below) 
 
Date and time  of 
initial observation 
 Season: 
Description of 
reaction   
 
 Geographical area: 
 
3. List of all medicines / Formulations including drugs of other systems used by 
the patient during the reporting period: 
 
Medicine Daily 
dose 
Route of 
administration 
& Vehicle – 
Adjuvant 
Date  Diagnosis for 
which medicine 
taken  Starting Stopped 
Siddha 
 
 
 
 
     
Any other 
system of 
medicines 
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4. Brief details of the Siddha Medicine which seems to be toxic : 
Details Drug – 1 Drug – 2 Drug - 3 
a) Name of the medicine    
b) Manufacturing unit and 
batch No. and date 
   
c) Expiry date    
d) Purchased and obtained 
from 
   
e) Composition of the 
formulation / Part of the 
drug used 
   
b) Dietary Restrictions if any 
c) Whether the drug is consumed under Institutionally qualified medical supervision 
or used as self medication.  
d) Any other relevant information. 
 
5. Treatment provided for adverse reaction: 
 
 
6. The result of the adverse reaction / side effect / untoward effects (please 
complete the boxes below) 
Recovered:           Not 
recovered: 
 Unknown: Fatal: If Fatal 
Date of death: 
Severe:   Yes   /   
No. 
Reaction abated after drug stopped or dose reduced: 
 
Reaction reappeared after re introduction: 
 
Was the patient admitted to hospital? If 
yes, give name and address of hospital 
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7. Any laboratory investigations done to evaluate other possibilities?  If Yes 
specify:  
 
8. Whether the patient is suffering with any chronic disorders? 
Hepatic    Renal    Cardiac    Diabetes    Malnutrition    
 
Any Others  
 
9. H/O previous allergies / Drug reactions:  
 
10. Other illness (please describe): 
 
 
11. Identification of the reporter: 
 
Type (please tick):  Nurse / Doctor / Pharmacist / Health worker / Patient / Attendant / 
Manufacturer /                                                                      
                                Distributor / Supplier / Any others (please specify) 
Name: 
 
Address: 
 
Telephone / E – mail if any : 
 
 
 
Signature of the reporter:       Date: 
Please send the completed form to:  
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           The Director 
            National Institute of Siddha, 
                                                           (Pharmacovigilance Regional Centre For Siddha 
Medicine), 
                                                           Tambaram Sanatorium, Chennai-600 047. 
                                                            (O) 044-22381314       Fax : 044 – 
22381314 
        Website : www.nischennai.org  
        Email: nischennaisiddha@yahoo.co.in   
 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ** * * * *  
This filled-in ADR report may be sent within one month of observation 
/occurrence of ADR   
 
 
 
Date:                                                                              
Station:  
 
Signature of the Investigator: 
Signature of the Lecturer:                                                             
         
Date :      
Station: 
 
Signature of the Investigator: 
Signature of the Lecturer:                                                         
    Signature of the HOD 
Name & address of the RRC-ASU / 
PPC-ASU 
Who Can Report?     
 Any Health care professionals like Siddha Doctors /  Nurses / Siddha 
Pharmacists / Patients etc.  
What to Report?  
All reactions, Drug interactions,  
Confidentiality  
 The patient’s identity will be held in strict confidence and protected to the 
fullest extent.  
 Submission of report will be taken up for remedial measures only not for legal 
claim  
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
POST-GRADUATE DEPARTMENT OF MARUTHUVAM 
CLINICAL EVALUATION OF SIDDHA DRUG,POORA PARPAM (Internal) 
NATHAICHOORI ENNAI(External)IN THE TREATMENT OF   
KEELVAYU(OSTEOARTHRITIS) 
Name of Principal Investigator:     Reg. No :  
 
FORM  -VII  DIETARY ADVICE FORM 
§º÷ì¸ ÜÊÂ ¯½×¸û ¾Å¢÷ì¸ §ÅñÊÂ¨Å¸û 
¸¡ö¸û (Vegetables): 
 ¸ò¾Ã¢ôÀ¢ïÍ (Unripe brinjal) 
ÓÕí¨¸ôÀ¢ïÍ (Unripe drumstick) 
«Å¨ÃôÀ¢ïÍ (Unripe Dolichos bean) 
¸£¨Ã¸û(Greens): 
¦À¡ýÉ¡í¸ñ½¢ (Sessile plant [Alternanthera 
sessilis] ) 
ãì¸¢Ãð¨¼ (Hog weed [Boerhaavia diffusa] ) 
àÐ§Å¨Ç (Climbing brinjal [Solanum 
trilobatum] ) 
ÓÕí¨¸ì¸£¨Ã (Leaves of Drumstick [Moringa 
oleifera] ) 
¸È¢§ÅôÀ¢¨Ä (Curry leaf [Murraya koenigii] ) 
Ó¼ì¸Úò¾¡ý (Winter cherry [Cardiospermum 
halicacabum] ) 
«Ú¸£¨Ã (Amaranthus tristis) 
¸Ã¢º¡¨Ä (trailing eclipta [Eclipta prostrate] ) 
ÀÆí¸û(Fruits): 
Á¡Ð¨Ç (Pomegranate) 
¬ôÀ¢û (Apple) 
ÀôÀ¡Ç¢ (Papaya) 
¬ÃïÍ (Orange) 
§ÀÃ£î¨º (Dates) 
«ò¾¢ (Fig) 
¿¡Åø (Jambul [Syzygium cumini] ) «¨ºÅõ 
(Non-vegetarian diet): 
¦ÅûÇ¡ðÎì¸È¢ (Meat)  
¸¡¨¼ (Quail) , º¢Ú þÈ¡øÁ£ý (Prawn) 
Í¨Ã (Bottle gourd) 
âº½¢ (Pumpkin) 
¦ÅûÇÃ¢ì¸¡ö (Cucumber) 
Ò¼¨Ä (Snake gourd) 
À£÷ìÌ (Ridged gourd) 
¯ÙóÐ (Black gram) 
¦Á¡î¨º (Indian butter Bean) 
¸¡Ã¡Á½¢ (Cow gram) 
¦¸¡ûÙ (Horse gram) 
¸ÎÌ (Mustard) 
±ñ¦½ö (Gingelly oil) 
ÒÇ¢ôÒ (Sour) 
¯ôÒ (Salt) 
Å¡Ôô ¦À¡Õð¸û (Vatha diet) 
¯Õ¨Çì ¸¢ÆíÌ (Potato) 
Å¡¨Æì ¸¡ö (Plantain) 
Ò¨¸Â¢¨Ä (Tobacco) 
ÁÐ «ÕóÐ¾ø (Alcohol) 
¦Àñ§À¡¸õ (þîº¡ Àò¾¢Âõ)  
[Sexual intercourse] 
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  ÁÕòÐÅ «È¢×¨Ã: 
®ÃÁ¢øÄ¡ò ¾¨ÃÂ¢Öõ, ÀÎì¨¸Â¢Öõ ÀÎò¾ø §ÅñÎõ, 
  ÌÇ¢÷ ¸¡üÚ ÀÎõÀÊÂ¡É þ¼ò¾¢ø þÕôÀ¨¾ò ¾Å¢÷ì¸×õ. 
¯¼ø «¾¢¸ ±¨¼ þÕôÀ¢ý ±¨¼¨Âì Ì¨Èì¸ §ÅñÎõ. 
«¾¢¸ àÃõ ¿¼ò¾ø, «¾¢¸ §¿Ãõ ¿¢üÈø ¾Å¢÷ì¸×õ 
 
  
   
Photos 
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UNPURIFIED POORAM 
 
 
 
 
POORA PARPAM  
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MUTRINA NATHAI CHOORI VEER   
 
 
 
VASAMBU  
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GARLIC 
 
 
 
ONION 
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Op no: H15914     Age/Sex: 59/M 
 
 
 
Op no: H29115     Age/Sex: 57/F 
 
 
 
 
 
   
Biochemical Analysis  
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 BIOCHEMICAL ANALYSIS OF POORA PARPAM 
 
S.No EXPERIMENT OBSERVATION INFERENCE 
 1.Test For Acid Radicals   
1. Test For Sulphate :  
       2ml of the above prepared extract 
is taken in a test tube to this added 
2ml of 4% ammonium oxalate 
solution. 
 
No cloudy     
appearance present 
 
Absence of Sulphate 
2. Test For Chloride: 
      2ml of the above prepared extract 
is added with 2ml of dil- HNO3 till 
the effervescence ceases. Then 2 ml 
of silver nitrate solution is added. 
 
Cloudy appearance 
present 
 
 Absence of Chloride 
s Test For Phosphate: 
      2ml of the extract is treated with 
2ml of ammonium molybdate 
solution and 2ml of con.HNO3 
 
 No colour     
appearance 
 
Absence of  Phosphate     
4. Test For Carbonate:  
    2ml of the extract is treated with 
2ml magnesium sulphate solution 
 
Cloudy appearance 
present 
 
Absence of  Carbonate 
5. Test For Fluoride & Oxalate: 
    2ml of extract is added with 2ml of 
dil. Acetic acid and 2ml calcium 
chloride solution and heated. 
No cloudy appearance 
present. 
      
 Absence  of     fluoride 
and   oxalate 
6. Test For Nitrate: 
   1gm of the substance is heated with 
copper turning and concentrated 
H2So4 and viewed the test tube 
vertically down 
 
 
No  Brown   gas   is 
evolved 
    
Absence   of   Nitrate 
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7. Test For Sulphide:  
      1gm of the substance is treated 
with 2ml of con. HCL 
No Rotten Egg 
Smelling gas  evolved 
Absence of   Sulphide 
8. Test For Nitrite: 
    3 drops of the extract is placed 
on a filter paper, on that - 2 drops 
of acetic acid and 2 drops of 
Benzidine solution is placed. 
No   Characteristic    
changes 
Absence  of  Nitrite 
9. Test For Borate: 
     2 Pinches of the substance is 
made into paste by using sulphuric 
acid and alcohol (95%) and 
introduced into the blue flame. 
Bluish  green  colour  
flame  not  appeared 
Absence   of   Borate 
 II. Test For Basic Radicals   
1. Test For Lead: 
      2ml of the extract is added with 
2ml of potassium iodine solution. 
No yellow precipitate 
is obtained. 
Absence  of   Lead 
2. Test For Copper: 
     2ml of extract is added with 
excess of ammonia solution. 
No blue color    
precipitate formed. 
 
Absence   of   Copper 
 
3. Test For Aluminium: 
    To the 2ml of extract sodium 
hydroxide is added in drops to 
excess. 
No characteristic 
changes.  
  Absence   of Aluminium 
4. Test For Iron: 
a.       To the 2ml of extract add 
2ml of  ammonium thiocyanate 
solution 
b.    To the 2ml of extract 2ml  
ammonium  thiocyanate solution 
and 2ml  of con HNO3 is added 
Mild red colour appear 
Blood red colour 
appeared. 
 Absence  of Iron 
 
Absence  of iron 
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5. Test For Zinc:  
        To 2ml of the extract sodium 
hydroxide solution is added in drops 
to excess  
 
White  precipitate   is   
not formed 
Absence of  Zinc 
6. Test For Calcium:  
        2ml of the extract is added with 
2ml of 4% ammonium oxalate 
solution  
Cloudy appearance and 
white precipitate is not 
obtained 
 
  Presence of  Calcium 
7. Test For Magnesium:  
     To 2ml of extract sodium 
hydroxide solution is added in drops 
to excess. 
White precipitate is  not 
obtained 
Absence    of Magnesium 
8. Test For Ammonium: 
      To 2ml of extract few ml of 
Nessler's reagent and excess of 
sodium hydroxide solution are 
added. 
No Brown colour 
appeared 
 
Absence     of Ammonium 
9. Test For Potassium:  
   A pinch of substance is treated 
with 2ml of sodium nitrite solution 
and then treated with 2ml of cobalt 
nitrate in 30% glacial acetic acid. 
 
No Yellowish 
precipitate is obtained. 
 
Absence of  Potassium 
10. Test For Sodium: 
    2 pinches of the substance is made 
into paste by using HCl and 
introduced into the blue flame of 
Bunsen burner. 
  
No Yellow   colour    
flame appeared 
   
Absence  of   Sodium 
11. Test For Mercury:  
      2ml of the extract is treated with 
2ml of sodium hydroxide solution.  
 
No yellow precipitate 
is obtained 
    
Absence of  Mercury 
12. Test For Arsenic:  
      2ml of the extract is treated with 
2ml of sodium hydroxide solution. 
 
No brownish red 
precipitate is obtained 
 
absence  of   Arsenic 
136 
 
 III. Miscellaneous   
1.  Test For Starch:  
  2ml of extract is treated with weak 
iodine solution  
 
Blue   colour 
developed 
 
  Absence of   Starch 
2.  Test For Reducing Sugar:  
    5ml of Benedict's qualitative 
solution is taken in a test tube and 
allowed to boil for 2 minutes and 
added 8 to 10 drops of the extract 
and again boil it for 2 minutes. The 
colour changes are noted. 
 
Brick   red  colour 
developed 
 
 Absence of  Reducing 
sugar 
3.  Test For The Alkaloids: 
a)  2ml of the extract is treated with 
2ml of potassium lodide solution. 
b)  2ml of the extract is treated with 
2ml of picric acid. 
c)  2ml of the extract is treated with 
2ml of phosphotungstic acid. 
 
 
  
Yellow   colour 
developed 
 
 
 
  Presence of   Alkaloid 
4.  Test For Tannic Acid:  
    2ml of extract is treated with 2ml 
of ferric chloride solution  
 
Block precipitate   is 
obtained 
 
 Presence of  Tannic acid 
5.  Test For Unsaturated Compound:   
     To the 2ml of extract 2ml of 
Potassium permanganate solution is 
added.  
 
Potassium 
permanganate is  not 
decolourised 
 
Absence   of     unsaturated 
compound  
6.  Test For Amino Acid: 
    2 drops of the extract is placed on 
a filter paper and dried well.. 
 
 Violet   colour 
developed 
 
Presence  of  Amino acids 
7. Test For Type Of Compound: 
    2ml of the extract is treated with 2 
ml of ferric chloride solution.  
 No Brown    colour 
developed 
No red colour 
developed  
Absence of  Oay  quinole, 
Pinephrine  and  Pyro 
catechol 
Anti pyrine,Alipathic 
amino acids and meconic 
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No violet colour 
developed  
 
No Blue colour 
developed. 
acid are absent. 
 
Salicylate and resorcinol 
are absent. 
 
Morphine, Phenol cresol 
and hydroquinone are 
absent 
 
RESULTS 
 Calcium 
 Tannic acid 
 Alkaloids 
 Amino acids are the chemical constituents present in POORA PARPAM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Physicochemical 
Analysis 
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PHYSICO-CHEMICAL ANALYSIS OF POORA PARPAM (ICPOES 
METHOD) 
S.No Elements Wavelength (nm) Pooraparpam (mg/L) 
1 Arsenic As 188.979 BDL 
2 Calcium Ca 315.807 12.012 mg/L 
3 Cadmium Cd 228.802 BDL 
4 Copper Cu 327.393 BDL 
5 Iron Fe 238.204 01.854 mg/L 
6 mercury Hg 253.652 BDL 
7 Potassium K 766.491 53.421 mg/L 
8 Magnesium Mg 285.213 01.103 mg/ L 
9 Sodium Na 589.592 22.210 mg/L 
10 Nickel Ni 231.604 BDL 
11 Lead Pb 220.353 BDL 
12 Phosphorus P 213.617 26.741 mg/L 
13 Zinc Zn 206.200 01.421 mg/L 
 
 
 
PHYSICO-CHEMICAL ANALYSIS OF POORA PARPAM 
S.no Parameter Mean 
1 Loss on drying at 105°C 5.12% 
2 Total Ash 27.32% 
3 Water soluble ash 6.55% 
4 Acid insoluble ash 0.06% 
5 PH 5.80% 
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HR-SEM ANALYSIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Protocol 
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1. TITLE: CLINICAL EVALUATION OF SIDDHA DRUG, POORA PARPAM 
(Internal) NATHAICHOORI ENNAI (External) IN THE TREATMENT OF   
KEELVAYU (OSTEOARTHRITIS). 
 
2. STUDY NO                                     : 
 DATE OF SUBMISSION                 : 
 
 3. NAME OF THE INSTITUTION: 
  National Institute of Siddha 
  Tambaram Sanatorium, 
  Chennai-47 
  Telephone No : 044-22411611 
  Fax                  : 044-22381314 
  E.Mail             : nischennaisiddha@yahoo.co.in 
  Website            : www.nischennai.org 
 
4. NAME OF THE RESEARCH SCHOLAR: 
  Dr.G.KARPAGAM, 
  P.G.Student, I YR[2013-2014] , 
  Department of maruthuvam,                              
  National Institute of Siddha,                                               
  Chennai -47. 
 
5.NAME OF THE GUIDE: 
   Prof.Dr.S.MOHAN,.MD(S), 
   Director and head of the department, 
   Department of maruthuvam, 
   National Institute of siddha, Chennai-47. 
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6.BACKGROUND:     
            Siddha system is a most primitive system of medicine.Siddhars classified the 
diseases into 4448 and established a separate chapter.As per One such clinical entity 
is  keel vayu mentioned in Siddha Maruthuvam( pothu) . 
            According to Siddha Maruthuvam(Pothu)
 
the signs and symptoms of KEEL 
VAYU  is,  pain&sweliing in knee joints, morning stiffness,  restricted movement, 
difficulty to walk, can be correlated with OSTEO ARTHRITIS(KNEE) in Modern 
Science  
OSTEO ARTHRITIS is the most common form of arthritis.  Approximately  
80-90% of  individuals older  than  65 years  have  evidence of primary OA. In India  
knee osteoarthritis is more common  in females than males  and it the most frequent 
joint disease with prevalence of   22-39%. 
      Since large number of patients with OA(100 Patients/day) are reporting the 
OPD of Ayothidoss  Pandithar  Hospital, which made  me to select this disease for my 
dissertation work.   
              The safety Studies of  POORA PARPAM  has been completed as a 
Dissertation  work at NIS(Referrence:Dissertation -187(D), DR.MGR MEDICAL 
UNIVERSITY reg no:32093606,April-2012 , Department of nanju noolum maruthuva 
neethu noolum,National Institute of Siddha, chennai-47.and the trial drug not yet 
undergone for  any clinical trial in osteo arthritis.
 
      In the text veeramamunivar vagada thiratu “ POORA PARPAM “ a siddha 
formulation  has been specifically indicated for KEELVAYU.The mode of 
preparation seems to be simple  and cost effective. The main Ingredients of the above 
said formulation are Pooram(calomel), latex of Calotropis gigantea  has  anti vadha 
properties  as per siddha literature.  
 7. OBJECTIVE 
a.PRIMARY OBJECTIVE: 
             To study the siddha formulations ―POORA PARPAM”(Internal 
Medicine)& NATHAICHOORI ENNAI (External Medicine) in the treatment of ― 
KEEL VAYU‖(osteo arthritis) for the  management of pain. 
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b.SECONDARY OBJECTIVE: 
               To study keelvayu, on the basis of Envagai thervu, mukkutram, kalam,naadi, 
Neerkuri, Neikuri etc,,in order to evaluate the pathology. 
              To assess the predominance of the disease related  to age,sex,socio-economic 
status,occupation  and family history etc,. 
 
 8.STUDY DESIGN &CONDUCT OF STUDY: 
 STUDY TYPE      : An open clinical trial 
 STUDY PLACE: OPD&IPD of Ayothidoss Pandithar Hospital,National 
Institute of Siddha,Tambaram Sanatorium,Chennai-47. 
 STUDY PERIOD:12 Months 
 SAMPLE SIZE   :40 Patients  
 
9.TREATMENT 
a.POORA PARPAM(Internal Medicine)[ Ref:Veerama munivar vagada 
thiratu,part-2,S.P.Ramachandran,Edition-sep 1994 :pg.no-69&70].
 
DOSAGE                                           : 6 mgs twice a day 
ADJUVANT                                      : Ghee or   Butter (after food) 
COURSE                                           : 12days 
DURATION OF TREATMENT         : 8 Days 
DIETARY REGIMAN
 [8]
                   : Avoid salt and Tamarind 
                                                           Add - wheat rotti,ghee and butter. 
Every first day of break (radiating)starts with head bath with the paste of Ajowan 
seeds and cow‘s milk,etc.Dietary advice is strictly followed during the period of drug 
administration as well as radiating  period ,roasted salt intake is recommended. 
 
METHOD OF DRUG ADMINIDTRATION:Given for 4 days by a break of 4 days. 
Again the medicine is given for 4days. 
 
 b.NATHAICHOORI ENNAI(External Medicine)[ Ref: Sarabenthira vaithiya 
muraigal (Vatharoga sigichai)..sri.K.Vasudev sastri,B.A,Edition-4(nov-1998)] 
[9].
 
 DOSAGE: Sufficient quantity (80ml) 
Applied externally over the affected parts.  
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10. STANDARD OPERATING PROCEDURE FOR “POORA PARPAM”: 
Required raw drugs: 
 
1. Purified pooram (calomal) -3 1/4 varagan(13.65gms) 
2. Latex juice of Calotropis gigentia, linn        -14 palam(490 grms) 
3. Juice of Allium cepa,linn                              -14 palam(490 grms) 
SOURCE OF RAW DRUGS 
The above said raw drugs will be purchased from a well reputed country shop at 
Chennai .The raw drugs will be authenticated by Botanist NIS and Phormacogonist 
SCRI Arumbakkam, Chennai. The raw drugs will be purified and the medicine will be 
prepared as per SOP as  in the Gunapadam  Laboratory  of  NIS, Chennai.  
 
PURIFICATION OF INGREDIENTS: 
PURIFICATION OF POORAM:
 
Kammaru vetrilai-1/4 palam (8.75 Gms) 
Milagu –1/4 palam (8.75 Gms) 
Take the above mentioned 2 Ingredients, make a paste with water.Take 1.3lit  
water(1.padi) in mud pot, and the paste will be mixed to it.Take the pooram in dry 
clean cloth and tied together. pooram covered with the cloth will be immersed  into 
the water and constantly heated until  the water become ¾.then take the pooram out 
wash with pure water.  
 
ALLIUM CEPA: Peal off   the outer skin. 
METHOD OF PREPARATION: 
INGREDIENTS: 
1. Purified pooram(calomal)                            -3 1/4 varagan(13.65gms) 
2. Latex of Calotropis gigentia,linn                 -14 palam(490 grms) 
3. Juice of Allium cepa,linn                             -14 palam(490 grms) 
 
DRUG PREPARATION:  
Purified Pooram will be placed in a clean dry cloth, fully covered and tied 
together.The above mentioned quantity of latex  of Calotropis gigentia was taken in a 
mud pot and pooram covered with the cloth will be added into the erukan pal and 
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constantly heated until the  latex remaining in the pot totally dried out.Then it will be 
ground into paste with small onion juice and will be made into small pills and dried in 
shade.pills were placed in a mud plate and covered with similar size of mud plate.The 
margines of the plates will be covered with clay pasted cloth.The plates will be placed 
inside the pit and pudam will be carried out with 40 palam cow dung cakes(1400 
gms).Next morning the mud plates will removed and finished poora parpam will be 
collected.  
 
DRUG STORAGE: 
          The prepared drug will be stored in a clean and dry wide mouthed glass 
container. 
 
DISPENSING: The prepared drug will be dispensed in sachets (6 mg each) Patients 
will be advised to collect the medicines once in 4days for8days. At each visit the 
patients will be advised to return the unconsumed drug if   any. 
 
STANDARD OPERATING PROCEDURE FOR “NATHAICHOORI ENNAI”: 
 Required raw drugs:  
1. Mutrina nathaichoori ver(Spermacoce hispida,linn)-3 palam(105gms) 
2. Vasambu ( Acorus calamus,linn)                  -3/4 palam(26.25gms) 
3. Poondu (Allium sativum,linn)                       -1/4 palam(8.75gms) 
4. Amanaku ennai (Ricinus communis,linn)    -1 padi(1.3 lit) 
 
PURIFICATION OF TRIAL DRUGS: 
ROOT OF NATHAI CHOORI: Wash with water 
VASAMBU          : Burnt the acorus calamus until it  turned  into charcoal. 
POONDU                :  Peel off the outer skin 
METHOD OF PREPARATION: 
Take above mentioned 3 drugs and make it paste mixed with castor oil allowed to boil 
and finally the oil will be filtered..  
DRUG STORAGE: 
          The prepared oil will be stored in a clean and dry wide mouthed glass bottle. 
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DISPENSING: The prepared oil will be dispensed in bottle (80 ml) once in 4days for 
8 days. 
11.   SUBJECT SELECTION: 
  As and when patients  reporting at OPD, Ayothidoss Pandithar Hospital, NIS 
with  symptoms of inclusion criteria will be subjected  to screening  test   and   
documentation  will be  done  by  using  screening  proforma . 
12.   SELECTION CRITERIA: 
         INCLUSION CRITERIA: 
Patients who will be ful fill any of the following criteria will be included in the 
study: 
 Age: 30- 60Yrs 
 Sex – Both male and female 
 Patients who will be having classical symptoms of pain &swelling of knee 
joints,stiffness&restricted  movements . 
 X-ray knee joint showing osteo arthritis 
 Willing to give blood samples for before and after treatment. 
 Patient willing to sign the informed consent stating that he/she will 
conscientiously stick to the treatment during 8 days but can opt out of the 
trial of his/her own conscious discretion. 
 Patients who are willing to take radiological investigations. 
 EXCLUSION CRITERIA:  
A potential subject who will meet any of the following criteria will be excluded from 
participation in this study: 
• Rheumatoid arthritis 
• Gouty arthritis 
• Tuberculosis 
• Diabetus mellitus 
• Hypertension 
• Any other serious systemic  illness 
• Cardiac disease 
• Chronic kidney disease. 
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WITHDRAWAL CRITERIA: 
• Intolerance to the drug and development of any serious adverse reactions 
during the trial period. 
• Patient turned unwilling to continue in the course of clinical trial. 
• Increase in severity of symptoms.  
• Patient will not take medication regularly.  
 
13. ASSESSMENTS AND INVESTIGATIONS: 
a) Clinical assessment 
b) Siddha assessment 
Routine investigations: 
1. Modern parameters 
2. Siddha parameters 
b) Specific investigations 
 
a)CLINICAL ASSESSMENT: 
o Pain on knee joints 
o Swelling 
o Tenderness 
o Joint stiffness 
o Movement restrictions 
 
SIDDHA ASSESSMENT: 
Enn vagai thervu ( Eight types of Examination): 
 Naadi 
 Sparisam 
 Naa 
 Niram 
 Mozhi 
 Vizhi 
 Malam 
 Moothiram    
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Siddha parameters: 
 Malam         -  Niram: 
                     -  Elakal / Erukal: 
                     -  Muraigal (Times / day) : 
 
 Moothiram (urine): 
 Neerkkuri (urine signs):                                         Neikkuri: 
i. Niram: 
ii. Edai: 
iii. Manam: 
iv. Nurai: 
v. Enjal 
 
b) ROUTINE INVESTIGATIONS:   
a.Haematology 
b.Blood sugar level  - Fasting (mg/dl) 
                                Post prandial (mg/dl) 
                                      Random (mg/dl) 
c.Lipid profile          
d.Renal function test:  urea,  
                                   Creatinine, 
                                   uric acid.     
e.Liver function test     
f.Urine routine 
g.Motion test                  
. 
c) SPECIFIC INVESTIGATION: 
 X RAY(KNEE JOINTS) 
 ASO Titre  
 CRP 
 RA factor 
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PATIENT SCREENING 
 
INCLUSION / EXCLUSION 
INCLUSION CRITERIA 
EXCLUSION CRITERIA 
 EXCLUDED FROM TRIAL 
14. METHODOLOGY 
           STUDY NUMBER 
          HISTORY TAKING 
       LAB INVESTIGATION 
              TRIAL DRUG  
   GENERAL  TREATMENT, 
                     OPD  
NATIONAL INSTITUTE OF  
                   SSIDDHA 
 
 
       CLINICAL ASSESSMENT 
 
OUTCOME 
     IF ANY ADVERSE EVENT 
         REACTION 
 TREATED IN OPD/REFERRED TO 
NEARBY GH 
INFORM ABOUT STUDY AND 
TRIAL DRUG 
  INFORMED CONSENT FORM 
REFERRED TO 
PHARMACOVIGILANCE DEPT OF    
NIS 
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15. STUDY ENROLLMENT: 
 
 In this clinical trial, patients reporting at OPD 1 Department of Maruthuvam, 
Ayothidoss Pandithar Hospital,NIS with the clinical symptoms of  pain on 
knee joints ,swelling ,stiffness&restricted movements,pain present in all limbs 
will be examined clinically for enrolling in the study based on the inclusion 
and exclusion criteria.  
 The patients enrolled in this study will be informed about the objective of the 
study, trial drug, possible outcomes in their own language and terms 
understandable to them. 
 After ascertaining the patient‘s willingness, informed consent will be obtained 
in the consent form. 
 All these patients will be given unique registration card which will contain‘s 
information regarding patients‘ Registration number, Address, Phone number 
and Doctors phone number etc. so as to report easily if any adverse reaction 
arise. 
 Complete clinical history, complaints and duration, examination findings-- all 
will be recorded in the prescribed Proforma in the case record form. Screening 
Form- I will be filled up; Form II will be used for recording the patients‘ 
history, clinical examination of signs and symptoms and laboratory 
investigations respectively.Patients will be advised to take the trial drug and 
appropriate dietary advice  would be given according to the patients‘ perfect 
understanding. 
 
16. CONDUCT OF THE STUDY:    
 
     Patients who have Satisified Incluction Criteria will be recruited for the Study 
Then   as Per Random Number Envelope which was serially kept and opened one by 
one for Allowing to a Particular Treatment Group. 
         As per siddha literature, before starting the treatment for  KEEL VAYU, 
purgation will be given with the OP medicine Agasthiar Kuzhambu 130 mg od with 
15ml  of notchi chaaru at early morning in empty stomach for one day
.
 
           Then the trial drug ―POORA PARPAM AND   NATHAI CHOORI 
ENNAI‖ 
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 is given  at a dose of 6 mg twice a day, 80 ml oil continuously for 4 days by a break 
of 4 days,patient should visit the hospital once in 4 days. At each clinical visit clinical 
assessment will be done and prognosis will be noted.   
       Laboratory investigations and x ray on knee joints will be done on 0th day and 
12
th
 day of the trial. For OPD patients, for further continuation of the treatment. 
        During the course of the treatment, patient is advised not to take tamarind,non-
vegetarian,   and advised to take the diet as given in Form VIII. If any of the trial 
patient who fails to collect the trial drug on the prescribed day but wants to continue 
in the trial, from the next day or two, he/ she will be allowed, but defaulters of one 
week and more will not be allowed to continue and be withdrawn from the study with 
fresh case being inducted 
Follow-up:After the end of the treatment ,the patient is advised to visit the OPD  for 
another 2months for follow-up.In this follow up period ,the patients clinical  
improvement will be documented.   
 
17. DATA MANAGEMENT:  
 After enrolling the patient in the study, a separate file for each patient will be 
opened and all forms will be filed in the file. Study No. and Patient No. will be 
entered on the top of file for easy identification.  Whenever the study patient 
visits OPD during the study period, the respective patient`s file will be taken 
and necessary recordings will be made at the assessment form or other suitable 
forms. 
 The screening forms will be filed separately. 
 The Data recordings will be monitored for completion by Guide (HOD, Dept. 
of Maruthuvam), SRO (Statistics) and the adverse event will be monitored by 
the members of the  Pharmacovigilance department of NIS . All forms will be 
further scrutinized in presence of Investigator by Sr.Research Officer 
(Statistics) for logical errors and incompleteness of data to avoid any bias. No 
modification in the results is permitted for unbiased reports. 
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16. OUT COME OF TREATMENT: 
PRIMARY OUT COME: 
[12] 
UNIVERSAL  PAIN ASSESSMENT SCALE: 
 
    0    :  No Pain 
   1 -3 :   Mild pain 
   4-6 :   Moderate pain 
           7-9      :          Severe pain     
          10        :          worst possible pain  
 
 
SECONDARY OUT COME:  
2. RESTRICTED MOVEMENT ASSESSMENT SCALE:                
Gradation of movements: 
 Grade 1 - Fit for all activities, do their work without support. 
 Grade II - Mild pain present in knee joint, mild restricted movements. 
 Grade III - Pain present in knee joint, moderate restriction of movements. 
 Grade IV - Severe pain, bed ridden. 
(Ref: Clinical manual for nursing practice (National Institute of Health Warren 
Grant Magnuson Clinical Centre) 
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17. ADVERSE EFFECT/SERIOUS EFFECT MANAGEMENT:  
If the trial patient develops any adverse reaction, he/she will be referred to the 
pharmacovigilance department of NIS. The members of this department will assess 
the adverse event and recorded in the prescribed adverse reaction form. For any AE 
the investigator (PG Scholar) will be given the proper management at NIS OPD with 
free of cost.  
 
18. STATISTICAL ANALYSIS:  
All the datawill be  entered  into computer  using MS Access software with 
macro for  logical  errors and manually cross checked  for  data  entry error.Then  the 
data will be exported to STATAL/SPSS Software for univariate/multivariate 
analysis.Student ‗t‘ test  and Paired ‗t‘ test and Mantel-Haenszel  chi-square test will 
be performed  for  determining the significance of a particular  effect variable. 
 
19.0 ETHICAL ISSUES: 
1. To prevent any infection, while collecting blood sample from the patient, only 
disposable syringes, disposable gloves, with proper sterilization of lab equipments 
will be used.  
2. No other external or internal medicines will be used. There will be no infringement 
on the rights of patient for this particular indication. 
3. The data collected from the patient will be kept confidentially. The patient        will 
be informed about the diagnosis, treatment and follow-up. 
4. After the consent of the patient (through consent form) they will be enrolled in the 
study. 
5.  Informed consent will be obtained from the patient explaining in the 
understandable language to the patient. 
6. Treatment would be provided free of cost. 
7. In conditions of treatment failure, adverse reactions, patients will be given 
alternative treatment at the National Institute of Siddha with full care throughout the 
end. 
 8. The patients who are excluded [as per the exclusion criteria] will be given proper 
treatment, at NIS.  
 
 
153 
 
ASSESSMENT FORMS: 
 
Form - I         Screening and Selection Proforma 
Form - II        Case record form 
Form - III      Laboratory investigation form 
Form – IV      Treatment Compliance form 
Form - V        Information sheet 
Form - VI Consent form 
Form -VII      Withdrawal form/ adverse drug reaction form/ Pharmacovigilance form 
Form –VIII Dietary Advice form. 
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SOPHISTICATED ANALYTICAL INSTRUMENT FACILITY 
IITM, CHENNAI-36 
PERKIN ELMER OPTIMA 5300 DV ICP-OES 
  
  
Sample ID                        Elements Symbol       Concentration 
                                       Wavelength (nm)  
 
 
POORA Parpam   -------------------------------------------------------------------------------
-------(wt:0.32810g) 
 
As 188.979 BDL 
Ca 315.807 12.012 mg/L 
Cd 228.802  BDL 
Cu 327.393 BDL 
Fe 238.204 01.854 mg/L 
Hg 253.652 03.215 mg /L 
K 766.491 53.421 mg/L 
Mg 285.213 BDL 
Na 589.592 22.210 mg/L 
Ni 231.604 BDL 
Pb 220.353 BDL 
P 213.617 26.741 mg/L 
Zn 206.200 01.421 mg/L  
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